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Abstract
Chapter 1. Cannabis, Cannabinoids, and the Endocannabinoid  System. A brief 
background on the discovery and pharmacology of cannabinoids and of cannabinoid receptors 
is described. This is complemented by a summary and comparison of the cannabinoid receptor 
affinities of various cannabinoid ligands, and a discussion of ligand binding assays, structure 
activity relationships, and ligand assisted protein structure experiments, and how data from 
these ligand evaluation methods guide rational ligand design. Additionally, early approaches 
developed for the production of synthetic cannabinoids are presented and discussed as they 
relate to the research conducted in the Tius group.
Chapter 2. The Total Synthesis of Ketocannabinoids Revisited. The early 
impediment which stalled the synthesis of target cannabinoid ligands but provided a side project 
that culminated in the abbreviated synthesis of ketocannabinoids is discussed. Prior published 
work describing the previous syntheses of ketocannabinoids is presented and the challenges 
encountered during their improvements are described. Notably, improvements herein are 
applicable to the synthesis of classical, non-classical, and hybrid cannabinoid classes, and have 
been demonstrated through the total synthesis of enantioenriched nabilone — a highly potent 
cannabinoid ligand in its own right, and whose racemate is a FDA approved pharmaceutical 
ingredient and arguably the most iconic ketocannabinoid.
Chapter 3. The Total Synthesis of C-9 and C-11 Functionalized Classical 
Cannabinoids. The total synthesis of a series of C-9 and C-11 functionalized tricyclic classical 
cannabinoids derived from enantioenriched nabilone is described. The synthesis of target 
ligands was performed primarily using simple functional group manipulations and relied upon a 
divergent nucleophilic displacement of organoiodide intermediates. Of note are the simple 
reaction conditions, and benign reagents employed for these transformations. Challenges 
encountered during the synthesis of the eight target ligands are described as well as the 
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solutions employed to overcome them. The pharmacological evaluation of target ligands is now 
charged to our collaborators at Northeastern University — the results of which will be published 
following completion.  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Chapter 1
Cannabis, Cannabinoids,
 and The Endocannabinoid System
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Cannabis sativa L. from the Latin canna, meaning reed, bis — in twos, and the adjective 
sativa for sown or cultivated, was aptly named.1 For millennia, cannabis has been cultivated for 
its abundant and uniquely useful fiber, flowers and seeds, and ancient pottery displaying 
cannabis fiber imprints have been found dating back as far as 10,000 years.2 While Cannabis 
sativa L. has three known species — sativa, indica, and ruderalis — it is most commonly 
referred to by colloquial terms depending on the resource for which it is grown; hemp for fiber 
and seeds, or marijuana for flowers (Figure 1). 
Ancient China is often referred to as the land of silk and hemp, and for good reason. The 
Chinese domesticated wild hemp and uncovered the utility of its fiber around 2800 BC.3 After 
proper retting,4a hemp fiber was pressed to make the first paper, braided into yarn, and the yarn 
was then used for clothes, ropes, and bowstrings. Due to hemp’s short agricultural cycle, its 
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Figure 1: Depictions of the Species of Cannabis sativa L.
fiber was readily available, and as an export helped ancient China develop into a super power. 
Although hemp grew naturally in many parts of Asia and India, it was not cultivated and used 
throughout the world until the pioneering work of the Chinese.5 Many countries relied upon 
hemp for its low cost and high strength especially for sailing canvas, rope and paper by which 
the written word could be spread. Hemp was brought to the Americas in the early 1600s6a and 
was such a valuable export to England, and necessity for colonial living that ‘must grow’ taxes 
were enacted in Jamestown in 1619. Massachusetts and Connecticut followed this precedent in 
1631 and 1632, respectively.6a With technological advances in the harvest and retting of hemp, 
the potential uses for this fiber were all but limited by human imagination.4b Cultivation of hemp 
in the United States, however, was outlawed in the 1930s and has only recently begun to 
resurge.6b
Cannabis sativa’s other cultivar, marijuana, also has deep roots in celestial China. 
Between the legends of Fu Hsi, Shen Nung, and Huang Ti, as well as writings and artifacts of 
the time, historians claim marijuana has been ingested for medicinal and spiritual purposes as 
early as 2800 BC.3,5 This is further supported by a recent excavation which discovered 3 pounds 
of preserved marijuana in the Yanghai Tombs of the Gobi Desert dating 700 BC.7 Marijuana’s 
incorporation in traditional chinese medicine has been well documented and appears with 
extensive detail in the oldest known copies of The Pen Ts’ao’, dating 50 AD. Marijuana’s utility in 
chinese medicine was highlighted by its analgesic use — in combination with wine — during 
challenging abdominal surgeries performed by Hua T’o in the second century AD.5
Preparations of marijuana differ by country and time period, but traditionally the flowers 
of a marijuana plant are smoked or ingested, combined with other spices and ingredients into a 
paste such as bhang, or suspended in alcohol as tinctures. Similar preparations can be applied 
to the clays and creams of hashish and charas, which are the compiled resinous deposits found 
on the leaves and flowers of marijuana.8,9 
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The dispersion of marijuana from central Asia followed much the same trend as hemp, 
and as its use spread, so did the conjecture that marijuana palliated earaches, bladder 
infections, memory issues, palpitating hearts, insomnia and numerous other ailments. This led 
to the widespread use of marijuana leading into the 19th century despite the fact that little was 
known about its mechanism of action. Conventional bioassays of the 1800s involved 
administration of marijuana to dogs, resulting in ataxia for active extracts and tinctures.10 
Although canine ataxia was consistent with central nervous system (CNS) activation, little else 
regarding what was in cannabis, or how it worked could be determined using the tools available.
Journals and communications in the mid 1800s report physicians observing assorted, 
and sometimes contradictory results upon marijuana administration. The variation of results was 
later traced back to the country and species from which the particular hashish or marijuana 
extracts were produced.11 Although C. indica, the second species of Cannabis sativa L., had 
been recognized by the late 1700s due to its differing shape, foliage, flowering and region of 
growth, this may have been the first distinction of the two by their medicinal qualities.11 
Furthermore, this hinted at the complex combination and natural variation of biologically active 
constituents within cannabis.12 In fact, modern techniques of separation and isolation13a applied 
to marijuana have resulted in the discovery of more than 420 small molecules produced by 
cannabis. Many of these are terpenes known for their aroma and medicinal utility, and are 
characteristically found in other plants (Figure 2).12
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By 1899, interest in the active principles of cannabis led Wood and coworkers to distill 
alcoholic charas extracts under reduced pressure.13 This distillation produced a crude red oil, 
named cannabinol that was subjected to degradation studies to determine its structure. A single 
component was isolated and characterized as C21H25O2, and was shown to contain a hydroxyl 
group. Cannabinol (CBN) thus became the first known compound intrinsically produced by 
cannabis, or phytocannabinoid described.14 Unfortunately, the complexity of the original charas 
was not detected by Wood’s experiments and cannabinol would remain the only known 
component of cannabis for thirty years. Moreover, the active components of charas were not 
carried forward following distillation, which was confirmed by the greatly diminished biological 
activity of the red oil. Limited by the tools of the 19th century, little progress was made to further 
determine the components within marijuana. Ignorance of the identity of cannabis’ active 
components put the medical field in contention during the following decades, debating the 
precise utility of cannabis and which species, indica or sativa, held more promise.11,15
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Figure 2: Therapeutic Uses and Common Origin of Major Terpenes Within Cannabis Flower
Note; A:Anti, Br.: Bronchodilator, Ba.:,Bacterial, If.:Inflammatory, Fu.:Fungal, Se.:Septic, 
Ca.:Cancer, Is.:Ischemic, De.:Depressant, In.:Insomnia, Sp.:Spasmodic, Ao.:Anorectic, 
Ax.:Anxiety, Co.:Convulsive, Ag.:Analgesic
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Despite the International Opium Convention of 1925,16 which put forth sanctions that led 
to the Marihuana Tax Act of 1937 and eventual ban of cannabis,6a research of the illicit plant 
accelerated in the early 20th century. Cahn, in 1931, repeated the distillation of charas and 
isolation of CBN, and was able to propose structure 11 (Figure 3).17 Given the relative 
consistency of patient testimonials on the use of charas, and charas tinctures, as well as 
analytical data on cannabinol, cannabis was presumed to have only one active component.18 
However, Cahn’s isolated compound did not produce the characteristic ataxia in dogs, as the 
original charas had.19 The mild activity of CBN surprised Cahn and his contemporaries, but the 
structure he outlined helped guide synthetic efforts that would eventually elucidate the structure 
of CBN and other phytocannabinoids.
Following an uneventful decade, collaborative efforts by Levane, Todd and Adams in the 
early 1940s found other major constituents in marijuana.20 Using partial synthesis and isolation 
techniques, cannabidiol (12; CBD*) was discovered from cannabis extracts. Through 
hydrogenation, two olefins were confirmed from isolated CBD* although degradation studies 
could not determine the position of the internal double bond. Moreover, circular dichroism 
experiments revealed cannabidiol extracts to be non-racemic, further complicating its 
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Figure 3: Proposed Structure of CBN*, CBD*, and Racemic ∆6a,10a-THC
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elucidation because of the potential presence of three chiral centers. Additionally, treatment of 
extracted cannabidiol with pyridine hydrochloride by Adams and coworkers resulted in the 
formation of a ‘tetrahydrocannabinol’ many times more potent than cannabinol or cannabidiol in 
canine bioassays.20e This ‘tetrahydrocannabinol’ could also be found within charas extracts 
although its structure eluded its discoverers. Apace with this work, synthesis of biologically 
active racemic ∆6a,10a-tetrahydrocannabinol (13; Figure 3) was described, and when 
dehydrogenated with sulfur, cannabinol was obtained. Furthermore, when extracted cannabidiol 
was teated with acid to provide the elusive ‘tetrahydrocannabinol’ and then oxidized, analytically 
pure CBN was obtained. These experiments confirmed Cahn’s proposed dibenzopyran 
fragment (11) while fully elucidating the correct structure of cannabinol (15; Figure 4).20a,c 
Levane, upon the re-inspection of the 100-lb lump of charas that help to discover 
cannabidiol and the ‘tetrahydrocannabinol’, found that CBN was the resulting product of 
spontaneous decomposition. The transformation of the active constituents of charas to the 
inactive CBN was confirmed by prolonged exposure of charas to air or refluxing its alcoholic 
extracts.18 This discovery supported previous observations of declining biological activity in 
aging charas, hashish, marijuana, and their corresponding tinctures.21
The tools of the 1940s were unable to confirm the position of the double bonds, or the 
orientation of stereocenters within cannabidiol or the related ‘tetrahydrocannabinol’.20d As such, 
further characterization of CBD and ‘tetrahydrocannabinol’ was prevented until nuclear magnetic 
resonance (NMR) was available in the late 1950s. Following this, Mechoulam and Gaoni 
published a seminal paper in 1964, incorporating 1H NMR spectroscopy into their structure 
elucidation. This account detailed the purification of hashish by chromatography which allowed 
for the isolation and characterization of three major compounds:  cannabidiol 14, cannabinol 15, 
and — for the first time — ∆9-tetrahydrocannabinol (∆9-THC, 16; Figure 4).22 After 
administration of the three purified components of hashish to canines, ∆9-THC resulted in 
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characteristic ataxia comparable to that of the pre-purified hashish. Isolated cannabidiol and 
cannabinol did not produce the same CNS activation when administered to canines, thus ∆9-
THC was identified as the major psychoactive constituent of cannabis. 
A year after the correct structures of 14 and 16 were described, the first total synthesis of 
racemic trans-∆9-THC and CBD was carried out by condensation of olivetol and citral.23 A 
synthesis which replaced citral with (-)-verbenol (17) followed two years later, and provided 
enantioenriched trans-∆9-THC and CBD (Scheme 1).24 The key step in this synthesis was the 
Brønsted acid condensation which resulted in a mixture of the desired 19, as well as double (19-
dbl) and abnormal (19-abn) addition to the aromatic ring (a; Scheme 1). The production of 
byproducts was later determined to be a feature of all condensations using 18, resulting from 
the non-bulky n-pentyl chain which allows ortho-substitution to take place. This can be 
ameliorated by the one-pot condensation and in-situ cyclobutane ring opening of 19, leading 
directly to the unnatural and thermodynamically more stable ∆8 olefinic isomer ((-)-∆8-16, b; 
Scheme 1). Isomerization of the alkene was accomplished by treatment of (-)-∆8-THC with 
hydrogen chloride to form the C-9 tertiary halide, followed by dehydrohalogenation with sodium 
hydride to afford a primarily (-)-∆9-THC ((-)-16, c, d; Scheme 1). 
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Figure 4: Constituents Within Hashish Confirmed by 1H NMR
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This synthesis afforded (-)-16 in 19% overall yield using simple material and, crucially, 
avoided the challenging and lengthy extractions from hashish, charas, or marijuana flowers. 
This synthesis could be modified to produce CBD and CBN, and made it unnecessary to 
produce active cannabinoids from marijuana, a process that was (and is) limited by plant to 
plant variations in production and was challenged by the legal status of cannabis that 
complicated its procurement. The availability of synthetic ∆9-THC in its naturally occurring 
isomer was of particular interest to biologists and physicians attempting to determine 
marijuana’s role and mode of action within humans. Moreover, the synthesis described by 
Mechoulam allowed for rapid production of synthetic analogues which could be used to further 
determine the role of marijuana.
Though the Controlled Substance Act of 1970 categorized cannabis as a Schedule I 
narcotic with “…high potential for abuse… [and] no currently accepted medical use”,25 clinical 
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Scheme 1: Stereospecific Synthesis of (-)-∆9-trans-THC, (-)-16a 
aReagents and Conditions: (a) p-TsOH•H2O; (b) BF3•OEt2; (c) HCl(g), ZnCl2 
cat.; (d) NaH
OH
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trials of cannabis and ∆9-THC were burgeoning. Investigations of the benefits of marijuana for 
the treatment of alcohol dependence, glaucoma, asthma, epilepsy, cancer and chemotherapy 
related pain and nausea, appetite regulation, the gain or loss of weight, as well as depression 
took place throughout the 1970s.26 Despite the social pressure engendered by the often 
beneficial results revealed by these studies, federal courts have consistently ruled that cannabis 
containing (-)-∆9-THC remain a Schedule I narcotic in the US.
Perhaps influenced by the growing data from clinical trials, countries around the world 
began incorporating synthetic ∆9-THC and its analogues into their modern pharmacopeia. The 
utility of both (-)-∆9-THC and its analogue nabilone (20) could not be refuted by the US for long, 
and were given FDA approval in 1985 for chemotherapy related nausea under the trade names 
Marinol® and Cesamet® (Figure 5).28
` At the time Marinol and Cesamet were approved for prescription use, cannabimimetic 
activity, or the potency of cannabis, was still measured by the traditional bioassays in dogs, 
monkeys and mice.10 Characteristic results from these bioassays were consistently observed, 
but biologists worked fervently through the 1980s to determine a less cumbersome bioassay to 
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Figure 5: Currently Approved FDA Cannabinoids 
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evaluate the cannabimimetic activity in humans. Prior to 1984 it had been generally accepted, 
given the lipophilicity of cannabinoid structures and experimental evidence, that cannabinoids 
interact with cell membranes in a non specific manner.29 This was challenged in 1984 by the 
work of Howlett, with material provided by Pfizer, that showed that potent synthetic 
cannabinoids inhibited adenylyl cyclase in neuroblastoma cells, suggesting the involvement of a 
guanosine-protein coupled receptor (GPCR).30 In 1988, Devane in a collaboration with Howlett, 
showed the concentration dependent displacement of a highly potent radiolabelled cannabinoid 
[3H]-CP-55,940 (21; Figure 6) by ∆9-THC in a ligand binding assay (LBA). This confirmed a 
specific binding site on a protein within rat brain tissue.31 Further confirmation of the first 
cannabinoid receptor (CB1) was given when Matsuda cloned and expressed this GPCR from rat 
brain in 1990,31 followed by the expression of human CB1 in 1991 by Gerard.32  In 1993 Munro 
found, cloned and expressed a second cannabinoid receptor (CB2) within a preparation of a 
human promyelocytic leukaemic cell line (HL60).33  
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Figure 6: Radiolabelled High Affinity and Selective Tracer 
Cannabinoids
Note: h = human recombinant; r = rat
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Following the discovery of CB1 and CB2, positron emission tomography (PET) was used 
to determine the anatomical distribution of the cannabinoid receptors. During a PET scan, a 
highly potent, selective, and radiolabelled cannabinoid tracer, such as 22 or 23 (Figure 6),34 is 
administered intravenously. As tracers move through the bloodstream, the positrons emitted 
from radioactive isotopes are recorded and plotted. Overlay of a PET scan with computed 
tomography (CT) scans can then give a detailed tissue localization of positrons and therefore 
cannabinoid receptors.35 The highest concentrations of CB1 reside in the brain, specifically the 
cerebral cortex, hippocampus, cerebellum, striatum, globus pallidus, and substantia nigra — 
organs linked to the CNS, which is consistent with the observed cannabis and ∆9-THC induced 
psychotropic effects. This receptor is also distributed, albeit at lower concentrations, in the 
gastrointestinal tract, pancreas, testis, uterus, prostate, eyes, lungs, kidney, adipose tissue, and 
heart34a,35a In a complementary fashion, CB2 is only expressed in the brain during times of 
inflammation and at homeostasis is found in peripheral tissue, with high concentrations in the 
spleen, tonsils, immune cells, and thymus.34b Very recently CB2 has also been expressed in 
hippocampal principal cells.35c
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Figure 7: Agonist Activation of Gα of a Membrane Bound GPCR37
Note: Activation of Gα and Release Gβγ Complex Lead to Distinct Downstream Effectors
Although the dissemination of cannabinoid receptors is quite different, both are GPCRs, 
exemplified by coupling to the subunits (Gα, Gβ, Gγ) of a heterotrimeric guanosine protein, as 
well as the typical seven transmembrane α-helices weaving through the cell membrane (Figure 
7). 
Comparison of the amino acid sequences of CB1 and CB2 revealed a 44% overall, and 
68% transmembrane or intracellular domain homology.38 Moreover, the activation of either of 
these receptors by an agonist (a chemical that binds and activates a receptor to elicit a 
biological response) is accompanied by regulation of adenylyl cyclase. This is often observed by 
the regulation of cyclic adenosine monophosphate, or cAMP37a and mutagen-activated proteins 
(mAPs), as well as the modulation of ion channels. The regulations resulting from CB1 and CB2 
activation differ slightly,38 and are modified by variations in the agonistic functionality of the 
cannabinoids or ligands that bind to the receptors. Cannabimimetic activity is then dependent on 
receptor affinity and whether a ligand is a full, partial, neutral, inverse, or irreversible agonist 
(Figure 8).39
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Figure 8: Depictions of Ligand Definitions According to Biological Activity
Note: Basal Activity is the Physiological Response in the Absence of a Ligand39
Contemporaneously with studies that discovered CB2, an experiment was reported in 
which radioligand [3H]-HU-243 (24; Figure 6) was displaced by an endogenous molecule within 
porcine brain. After fractionation and chromatography of 4.5 kilograms of brain, 0.6 milligrams of 
arachidonoylethanolamine 25 (AEA) was recovered, and linked to this observation (Figure 9).40 
Competitive binding of endogenous, or internally biosynthesized, molecules to CB1 was 
unexpected, but led to the first understanding of the existence of the endocannabinoid system 
(ECS). The ECS is composed of both CB1 and CB2, as well as the endogenous ligands, 
enzymes responsible for ligand metabolism, and perhaps even unidentified components.41 
While understanding of the ECS continues to grow, this vast lipid signaling network has 
been shown to regulate many aspects of embryonic development and homeostasis including 
immunity and inflammation, apoptosis and carcinogenesis, neuroprotection and neural plasticity, 
pain and emotional memory, as well as hunger, feeding, metabolism, nociception, energy 
balance, and cardiovascular health.42 Given the diversity of functions that the ECS helps 
regulate, cannabinoid ligands have been developed to interrogate the selective activation of 
these functions. To this end, preparation of novel ligands with a high level of receptor specificity 
and affinity has been of paramount importance for the development of drugs which influence 
these systems.  
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Figure 9: Various Endogenous Cannabinoids
Ligand binding assays (LBAs) have aided in the design of new diverse and selective 
cannabinoids. A typical LBA uses radiolabelled cannabinoids such as [3H]-CP-55,940 or [3H]-
HU-243 (21, 24; Figure 6) called substrates, with known agonistic activity that are bound to a 
cannabinoid receptor. After complexation, a potential inhibitor of the radioligand — a yet 
unexamined cannabinoid ligand — is then introduced to the substrate-receptor complex in 
various concentrations. The amount of ligand incorporation, or substrate inhibition is measured 
by the resulting discharge of tritium labelled material. The concentration that results in a 50% 
reduction of substrate incorporation is designated as the IC50 for the inhibitor or ligand.43 Since 
the binding potential between radiolabelled substrates varies, the absolute inhibition constant, 
Ki, is derived using the Cheng-Prusoff equation (Equation 1).
(1) Ki = IC50/(1+[L]/KD)
Equation 1: Determination of Absolute Inhibition Constant
Note; [L]: Fixed concentration of  radioligand, KD: Half maximal activation of receptor by 
radioligand
Even though the Cheng-Prusoff equation is only applicable if the substrate and ligand 
bind competitively to the same site, the resulting absolute inhibition constant is directly 
comparable to other ligands.44 The process of using LBAs, though useful to determine the 
potency associated with a ligand, is cumbersome due to the inherent post-synthesis evaluation 
of ligands which leads to a type of hypothesis based methodology for targeted ligand design. 
For a more logical development of ligands, based on the receptor binding pockets and structural 
and chemical requirements for their activation, crystal structures of the cannabinoid receptors 
are necessary. 
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Since CB1 and CB2 are both GPCRs, crystallization of these proteins presents a 
challenge. Of the hundreds of diverse guanosine-protein coupled receptors known, there exist 
only a handful of accurate crystal structures. The challenge associated with the crystallization of 
GPCRs comes from their structural conformation, and more importantly, the conformation of 
their ligand binding pocket, which is dependent upon the cell membrane in which they reside.45 
This dependency often results in rapid conformational changes and denaturation of the protein 
outside of the cell membrane. This issue can usually be avoided with ligand-protein co-
crystallization, but attempts to use this technique on the cannabinoid receptors has resulted in 
significant conformational changes.44a Currently, attempts to crystallize the cannabinoid 
receptors are being performed with an appropriately truncated version of the proteins, 
potentially allowing greater stability and rigidity outside the cell membrane without 
conformational changes.46
The crystallization issues surrounding the cannabinoid receptors have prompted the 
development of the ligand-assisted protein structure (LAPS) technique by Makriyannis and 
coworkers.47 This experimental technique is used to obtain information about the key amino acid 
residues that interact with ligands. Complexation of high affinity ligands with a cannabinoid 
receptor, followed by covalent attachment of the ligand to the receptor, mediated by one or more 
reactive functional groups on the ligand, is followed by enzymatic degradation of the covalent 
ligand-receptor complex, resulting in the fragmentation of the protein to a number of peptides. 
Analysis and sequencing by mass spectrometry can then identify amino acid sites that interact 
with the complexed ligand. Using the primary amino acid sequence the location of the ligand 
binding pocket can then be determined by systematically exchanging labile amino acid residues 
with unreactive alternatives through site directed protein mutagenesis, the result of a series of 
cysteine exchanges are shown in Figure 10.47
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Although LAPS is challenging and does not reveal three dimensional information of the 
binding pocket, data obtained is used for computer modeling of the ligand-receptor complex and 
complemented by a ligand’s structure activity relationship (SAR). Through analysis of a ligand, 
taking into account the 3-dimensional structure, electron density, covalent or polar functionality, 
steric bulk, and flexibility, as well as comparing changes in receptor affinity, SARs can help 
determine which feature of the ligand is responsible for a change in biological activity. This can 
then be combined with data obtained from LAPS, making rational drug or cannabinoid design a 
more systematic and logical process.
The design of unique and interesting cannabinoids is nothing new, and even before 
LBAs, LAPSs, SARs, and the discovery of the endocannabinoid system, rational interpretation 
of empirical data was used to guide the production of synthetic cannabinoid analogues. The 
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Figure 10: Serpentine Representation of Site-directed Mutagenesis Performed on hCB247c
Note: Transmembrane Cysteine Residues Subjected to Mutation are Circle in Red
identification of pharmacophores, or structural features required for cannabimimetic activity, 
began in the 1940s with observations of cannabinoid analogues exhibiting various levels of 
potency. These pharmacophores were more easily interrogated in the 1970s, after the 
introduction of NMR and definitive structural elucidation of marijuana’s active components.20e,
55,56 Guided by the traditional bioassays, and then by more advanced CB1 and CB2 ligand 
binding assays, distinct cannabinoid pharmacological properties have been described, and are 
defined within the different classes of structurally distinct cannabinoids.
Initially, cannabinoids were defined as intrinsically produced compounds obtained from 
marijuana, hemp, or their extracts, but now have been subsumed into the much larger context of 
the endocannabinoid system. A cannabinoid, defined by contemporary standards, is a 
compound with direct or indirect activation of one or both cannabinoid receptors. Categorized by 
source, there exist endogenous, synthetic, and phytocannabinoids for those prepared by the 
body, the human, or the plant, respectively (Figure 11).14
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Figure 11: Classes of Cannabinoids
Since phyto- or endocannabinoids can be produced synthetically, classes based on 
source are not mutually exclusive. Additionally, each class contains direct ligands that bind to 
CB1 or CB2 as well as indirect ligands that influence cannabimimetic activity in some other 
manner, i.e. interfere with degradation pathways.14 Furthermore, ligands can interact at either 
allosteric or orthosteric binding sites of a cannabinoid receptor leading to various agonistic 
properties, creating further distinctions between cannabinoids. Subsequently, due to the large 
number of synthetic cannabinoids in production and being examined as novel drugs, synthetic 
cannabinoids have been split into sub-classes based on familiar structural features.
A number of synthetic cannabinoid classes, that bear little to no obvious structural 
homology with (-)-16, were developed by pharmaceutical companies and will be described only 
briefly.48 Diarylpyrazoles represent a structural motif researched by Sanofi-Aventis.49 
Rimonabant, (31; Figure 12) is a ligand belonging to this class, and shows extremely high 
receptor affinity and selectivity toward CB1. Aminoalkyl indole compounds, such as Pravadoline 
32 were initially developed by Sterling-Winthrop to take advantage of the dispersion of CB2 
throughout peripheral tissue, and act as non-steroidal anti-inflammatory drugs.50 Diarylsulfonyl 
ester 33 was developed by Bayer for analgesic and neuroprotective effects,51 and Japan 
Tobacco Company developed 34 and a number of other similar cannabinoids that act as CB2 
selective agonists.52
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Classical cannabinoids, like ∆9-THC, are the most recognizable class of synthetic (or 
phyto) cannabinoids, and are characterized by their chromane core and ABC ring system 
(Figure 13). Closely related are the non-classical and hybrid cannabinoids. Non-classical 
cannabinoids are defined by the open pyran B ring, typified by 36. The open bicyclic system of 
non-classical analogues can then be equipped with differing functionality at carbon atoms 6a 
and 6. Although synthetic non-classical cannabinoids appear peculiar, they are structurally 
related to cannabidiol (CBD, 14; Figure 4). Hybrid cannabinoids were originally described in the 
context of combining non-classical functionality at C-6a into a classical tricyclic skeleton.54 This 
work produced the first classical/ non-classical (CC/NCC) hybrid cannabinoids, but subsequent 
work has explored the combination of classical cannabinoids with aminoalkyl indoles.54e 
Classical/non-classical hybrid  cannabinoid 35 exemplifies its class, with functionality extending 
from C-6 of the classical B ring (Figure 13). These three sub-classes of phyto-inspired synthetic 
cannabinoids share three pharmacophores:  the northern aliphatic group, phenolic hydroxyl, and 
lipophilic or C-3 side chain.
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Figure 12: Structurally Diverse Synthetic Cannabinoids
The southern aliphatic hydroxyl group is a feature shared amongst non-classical and 
some hybrid analogues and refers to functionality at C-6a, or C-6, other than the classical gem-
dimethyl. The hydroxyl term was added after optimization of receptor affinity at Pfizer 
determined that an alkyl chain at C-6a with a hydroxyl group at the terminal carbon potentiated 
the ligand binding (Compare 38, 39; Figure 14).53
In the 1990s, Tius and coworkers complemented the work done at Pfizer related to 39, 
and explored the conformational requirements of a southern aliphatic hydroxyl group.54 By 
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Figure 13: Pharmacophores of Classical, Non-Classical, and CC/NCC Hybrid 
Cannabinoids 
Note: Dibenzopyran Nomenclature Shown for (-)-16
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Figure 14: Various Non-Classical Cannabinoids
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restricting the flexibility without changing the length of the southern alkyl chain of 39 (Figure 
14), the orientation of this hydroxyl was shown to have a profound effect on receptor affinity (41, 
42; Figure 15). Following this work it was determined that a C-6 β-iodoethyl or β-hydroxypropyl 
group further potentiate receptor affinity, as seen in C-11 hydroxy cannabinoids 43 and 44 
(Figure 15).54a
The northern aliphatic group is a pharmacophore common to classical, non-classical, 
and hybrid cannabinoids and refers to substitution at C-9 or C-11. These two positions have 
been extensively examined for their role in receptor affinity. The stereochemistry at C-9, the 
length of the C-9 substituent, the location of unsaturation in the C ring, and functionality at C-9 
or C-11 all influence cannabimimetic activity (Figures 16, 17).
Canine in vivo assays of early synthetic cannabinoids indicated the chirality at C-9 to be 
crucial for cannabimimetic potency.  Mechoulam found that hexahydrocannabinol 45, containing 
an equatorial methyl at C-9, was 20 times more potent than its axial isomer (46; Figure 16).55 
Cannabimimetic activity was further increased by the introduction of a hydroxyl group at C-9. 
May and coworkers found that equatorial C-9 alcohol 47 had potent activity in animal bioassays, 
whereas C-9 axial diastereomer 48 was inactive.56 The position of unsaturation in the C ring 
 35
Figure 15: Various Hybrid Cannabinoids
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also influences the potency of ligands. Interestingly, the naturally abundant ∆9 isomers show 
diminished receptor affinity compared to their ∆8 and ∆11 isomers (49, 50, 51; Figure 16).
A crucial feature that influences cannabimimetic activity is the BC ring junction 
stereochemistry. Although the B ring feature is absent in non-classical analogues, the absolute 
configuration at carbon atoms 6a and 10a is critical to receptor affinity in all non-classical, 
hybrid, and classical cannabinoids — as illustrated by the comparison of HU-210 with 
enantiomer HU-211 (52, 53; Figure 17).57
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Figure 16: Illustrations of Stereochemistry at C9 and Alkene Position
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Figure 17: Illustrations of Ring Junction Stereochemistry57b
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The phenolic functionality at C-1 is another common pharmacophore and key to CB1 
receptor affinity. Removing or masking the phenolic hydroxyl functionality greatly reduces or 
abolishes ligand binding to CB1, as a comparison of 54, 56, and 49 with 55, 57 and 58, 
respectively, demonstrates. (Figure 18).58,59 Interestingly, affinity to CB2 is only slightly affected 
by these changes. This illustrates a major difference in the binding pockets of the two 
cannabinoid receptors, and serves as a basis for the development of CB2 selective ligands.60
The C-3 side chain has been extensively examined in classical, non-classical and hybrid 
cannabinoids, and may be the most manipulated of all the pharmacophores. The relative 
flexibility, length, steric bulk, electronic properties, and functional groups present have all been 
scrutinized and Figure 19 serves as an abbreviated representation of the published results. 
Manipulations of the C-3 side chain can reveal the complexity of the cannabinoid binding 
pocket, but lipophilic substitution here is often accompanied by high receptor affinity.
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Figure 18: Replacement of Phenolic Hydroxyl and Effects on Receptor Affinity
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 Expanding on the discovery by Adams that a dimethylheptyl side chain, as in 49, 
potentiated ligand binding, a series of compounds were prepared to determine the trend 
between steric bulk at C-1’ and receptor affinity (59 - 62; Figure 19). Increasing the bulk 
throughout this series modulated receptor affinity, but no drastic change or trend in potency 
related to C-1’ bulk was borne out in the subsequent ligand binding assays (Figure 19).61a
Following the pharmacological evaluation of 62, the steric bulk at C-1’ required for 
receptor activation was probed, and led to the isobornyl and bornyl derivatives 63 and 64, 
respectively (Figure 19).61b Because the large caged structures were well tolerated by CB1 and 
CB2 binding pockets, adamantyl derivatives connected at C-2 (65) or C-1 (66) were synthesized 
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Figure 19: Increased Bulk and Unsaturation at C1’ of Classical Cannabinoids
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and evaluated (Figure 19). Not only were the adamantyl side chains tolerated but considerable 
receptor selectivity was exhibited by 66, however, the selectivity was the reverse of what had 
been noted for 63.61c The high receptor affinity, selectivity, and relative ease of synthesis has led 
to the preference for C-1 adamantyl side chains over their C-2 isomers.
The specificity of the cannabinoid receptor’s binding domain is highlighted when 
changes to the electronics and conformational flexibility of the lipophilic side chain are made. 
Unsaturation between C-1’ and C-2’ as in 68 and 69 leads to increased receptor affinity, and 
receptor selectivity is also modulated by either a cis or trans alkene at this position, however, no 
further increase in potency is noted when C-1’ and C-2’ are joined by a triple bond, as illustrated 
by alkyne 70 (Figure 19).62
Targeted covalent inhibitors (TCIs) represent an interesting development in cannabinoid 
ligands. These high affinity ligands are designed in parallel with LAPS experiments, and are 
equipped with reactive functional groups. Once a TCI is bound to a cannabinoid receptor, the 
reactive group comes in proximity to certain amino acid residues in or around the receptor’s 
binding site. By exploiting the reactivity of proximal amino acids, covalent bonds between the 
cannabinoid receptor and the labile functionality of a receptor bound ligand can then be formed. 
This is followed by LAPS experiments and site directed mutagenesis to determine precisely 
which amino acids form the covalent bonds, and in turn the approximate position of the binding 
pocket within the receptor protein. Installation of reactive functionality on various positions of a 
high affinity TCI scaffold can then probe and target different amino acid residues along the 
cannabinoid receptor sequence.63 Two major types of covalently activated cannabinoids have 
been employed as TCIs; those bearing electrophilic or photoactivatable functionality.
The most common electrophilic functional group used is an isothiocyanate (-NCS), which 
has previously been applied to the study of opioid,64 NMDA,65 and benzodiazepine66 receptors. 
Isothiocyanates react quite slowly with water, but under physiological conditions react to form 
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covalent bonds with thiol, hydroxyl, or amine nucleophiles. Such is the case for 71, which was 
the first CB2 selective covalent probe that led to the discovery of cysteine C6.47(247) as a 
critical amino acid adjacent to the CB2 binding pocket (Figures 10; 20).67 
Photoactivatable probes contain functionality with latent reactivity which permits them to 
access a binding pocket prior to activation. Following equilibration to form a ligand-receptor 
complex and photo-irradiation, reactions occur between the ligand and proximal amino acid 
residues. Photoactivatable probes have been used in the study of muscarine,68a serotonin,68b 
retinal receptors,68c and azides (-N3) are a commonly used photoactivatable moiety due to their 
ease of preparation and stability in the absence of light. Azides provide access, upon irradiation, 
to highly reactive intermediates which can be intercepted with a wide range of amino acid 
residues (72, 74; Figure 20).69
Ogawa prepared a number of classical cannabinoids (77 - 81) equipped with 
isothiocyanate, azide, and cyano (-CN) functionality at C-3’ of an adamantyl side chain to be 
used as targeted covalent inhibitors (Figure 21).70 Isothiocyanate and azide functional groups 
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Figure 20: Covalent Inhibitors of The Cannabinoid Receptors
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confer high affinity whereas precursor amine 75 is inactive at the cannabinoid receptors. 
Moreover all analogues in this series show markedly higher CB2 affinity than the unsubstituted 
76, and binding for both receptors was further potentiated when the reactive functional group 
was separated from the adamantyl core by a methylene group, as in 78, 80, and 82. 
Additionally, 77 - 82 function as agonists for CB1, but interestingly 77, 78, and 82 act as inverse 
agonists at CB2. It is also observed that 80 and 82 are irreversible agonists, making them ideal 
candidates for LAPS studies. These irreversible agonists are also being employed in attempts to 
co-crystallize ligand-receptor complexes.70
Spurred by the potency, agonism, and potential uses for Ogawa's ligands in LAPS and 
co-crystalization experiments, this thesis describes the preparation and evaluation of similar 
covalent probes appended at C-9 or C-11 of a classical cannabinoid scaffold (83 - 90; Figure 
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Figure 21: Classical Cannabinoid Targeted Covalent Inhibitors
Note: Ki* represents apparent Ki  for irreversible agonists
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22). In addition to azide, cyano, and isothiocyanate functionality, nitrate esters which can be 
regarded as nitric oxide (NO) generators, putatively responsible for the so-called endothelial 
derived relaxation factor,71 have also been prepared and their pharmacology has been 
examined.
The synthesis of classical cannabinoids has come a long way since the work of Todd 
and Adams, and many clever approaches have been applied to the production of these simple 
tricyclic molecules. Tetrahydrocannabinol (16) has been prepared by means of Brønsted or 
Lewis acid catalyzed condensation, lithio-anion or cuprate additions, cycloaddition reactions, 
and even Claisen rearrangements as the key step.72 Recently a stereodivergent catalytic 
synthesis has been performed to allow selective access to the four stereoisomers of 16.73 Many 
of these pathways however suffer from: unsatisfactory yields; formation of C-2 and C-4 
regioisomers upon terpene condensation with olivetol (see 19-dbl, 19-abn; Scheme 1); ring 
junction isomers at C-10a and C-6a, other than the naturally occurring R, R (c, Scheme 2); and 
difficulty avoiding the C-9 double bond isomerization to the thermodynamically more stable ∆8-
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Figure 22: Cannabinoid Receptor Probes Described in Chapter 3
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position (b, Scheme 1). Even after decades of synthetic effort, no single synthesis has 
appropriately addressed all of these issues;74 however, 83 — 90 share a common synthetic 
intermediate, 20, for which an effective, albeit flawed, synthesis was described nearly forty 
years ago (Schemes 2, 3).
The synthesis of racemic and optically active nabilone was originally described in great 
detail by Archer and coworkers at Eli Lilly Company (Scheme 2, 3).75 Racemic 20 was 
produced in four steps, starting from the achiral p-methoxy acetophenone or acetanisole 91. 
Standard methyl Grignard addition followed by a slightly modified Birch reduction afforded 
tertiary alcohol 92 in 56% over two steps (a, b; Scheme 2). The critical condensation and 
cyclization reaction was performed using a large excess of SnCl4 which was added to a mixture 
of 92 and dimethylheptyl resorcinol (93; c; Scheme 2). The initial attempts at this powerful 
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Scheme 2: Total Synthesis of Racemic Nabilonea
aReagents and Conditions: (a) MeMgBr, Et2O, 35 ºC, 3 h; 94%; (b) Liº, NH3(l), -78º C; 56% 
from 91; (c) SnCl4, CH2Cl2, 0 ºC, 7 h; 89% (4.5:1 cis:trans); (d) AlCl3, CH2Cl2, 0 ºC, 4 h; 92% 
(A) MeMgCl, THF, 10 ºC then ∆, 4.5 h; 94%; (B) Liº, NH3(g), t-BuOH, THF, -10 ºC; 58%; (C) 
Tf2O, ~30/1 v/v CH2Cl2/H2O, -20 ºC to 0 ºC; 83% (exclusively cis)
Note: A, B, C represent modifications as of 2010ref.76
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transformation produced low yields, but when water was used in addition to tin tetrachloride the 
yield of cis- and trans-(±)-20 improved dramatically to 89%. Although water improved the yield of 
the condensation/annulation, this reaction lacked stereospecificity, which led to the formation of 
both cis and trans nabilone as well as their enantiomers. The complex reaction mixture was 
simplified by treatment with aluminum chloride in a separate step, which led to the isomerization 
of racemic cis-nabilone to its epimer trans-nabilone, (±)-20, in 93% yield. These four steps 
provided trans-nabilone in 45% overall yield from p-methoxy acetophenone (Scheme 2).75 
The use of large quantities of tin tetrachloride near the end of the synthesis of (±)-20 is 
somewhat problematic. Removal of tin salt emulsions are difficult and have created 
experimental complications during extraction, and as racemic nabilone is intended for human 
consumption, the risk of tin exposure is a concern to patients as Cesamet® is often administered 
two or three times a day throughout the entirety of a chemotherapy cycle, greatly increasing the 
likelihood of tin exposure if it remains present in trans-nabilone.79b Moreover, regulatory bodies 
such as the United States Food and Drug Administration (FDA), have stringent quality control 
guidelines for active pharmaceutical ingredients (APIs). Although tin is a Class 3 element based 
upon its generally low toxicity and likelihood of exposure, its inorganic salts have been linked to 
anemia and chromosomal damage in rats.79a
To avoid the risk of tin exposure entirely, the synthesis of racemic 20 has been amended 
most recently by the replacement of tin tetrachloride with triflic anhydride (C; Scheme 2). As 
was found by Archer when employing tin tetrachloride, the yield of the annulation/condensation 
using triflic anhydride could also be improved by the introduction of water to this reaction, a 3:1 
mol ratio with 93 being optimal. Presumably the in situ generation of triflic acid is responsible for 
the improved yield, interestingly though, using triflic acid at the outset of annulation or triflic 
anhydride with a lower ratio of water (1:1 mol:mol with 93) reduced the yield of the intermediate 
(±)-cis-20 from 83% to 65% or 72%, respectively.76 Also described in the modified synthesis of 
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(±)-20 is a useful adaptation to the classic Birch reduction, in which gaseous ammonia is 
bubbled through the reaction medium at -10 ºC to produce 92, avoiding the use of a preparative 
scale -78 ºC reactor as well as the risks associated with large quantities of liquid ammonia (B; 
Scheme 2). With these modifications, the synthesis of (±)-20 can be performed without the use 
of heavy metal reagents, while increasing the overall yield by 9% on a 300 gram scale (Scheme 
2).76 
The production of (±)-nabilone is useful, as Cesamet is administered as a racemate of 
trans-nabilone, however, for the interrogation of CB1 and CB2, the pharmacological properties of 
new ligands and their agonistic potential with the cannabinoid receptors there is a need for 
enantiomerically enriched material to ensure optimum ligand binding and receptor potentiation, 
rendering a synthesis which provides racemic 20 unsuitable for the production of synthetic 
cannabinoids used in biological assays. Therefore an enantioselective synthesis of (-)-20 is the 
preferred method for the assembly of target ligands 83 - 90.
Although Archer and coworkers described a number of methods for the synthesis of 
optically active nabilone, two were especially successful and both start from enantioenriched, 
inexpensive (-)-β-pinene (94; Scheme 3).75 An impressively brief, four-step synthesis of (-)-
nabilone from 94 was developed (a, f, g, h; Scheme 3), however, the overall yield was 
unserviceable, providing less than 10% of (-)-20. The low yield (-)-nabilone from this route was 
presumed to be caused by the poor reactivity of apoverbenone 99, which led chemists to 
generate synthetic equivalents 97a or 97b. Diacetates 97 are very reactive, rendering them 
unstable at elevated temperatures, which contributes to the low yield of either 97a or 97b 
following vacuum distillation (c; Scheme 3). Moreover the ease with which 97a or 97b 
decompose at elevated temperatures requires their condensation with 93 to be carried out at 
ambient temperature lest they decompose to 99 (d; Scheme 3). After four hours at room 
temperature, exposure of either diacetate to a mixture of p-toluenesulfonic acid (p-TsOH) and 
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dimethylheptyl resorcinol produced 98, which was isolated in 70% yield after trituration with 
hexanes (d; Scheme 3). Further treatment of the white crystals of 98 with p-TsOH in refluxing 
chloroform led to a 2:1 cis:trans mixture of (-)-20 in 92% yield. Although cis-nabilone could be 
isomerized in a separate step to the trans (-)-20 in 70% yield by treatment with aluminum 
chloride, a one step conversion to (-)-20 was more practical, and treatment of 98 with tin 
tetrachloride provided trans-nabilone in 84% yield (e; Scheme 3). The five transformations from 
94, leading through either diacetate (97a or 97b), that eventuate in the isolation of (-)-20, were 
originally performed in 21% overall yield and the synthesis was deemed by Archer and his 
contemporaries as the most convenient preparation of (-)-nabilone (a, b, c, d, e; Scheme 3).
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Scheme 3: Total Synthesis of Optically Active Nabilonea
aReagents and Conditions: (a) O3, CH3OH/CH2Cl2, -78 ºC, ii. Me2S, -78 ºC to rt; 89%; (b) 
isopropenyl acetate, p-TsOH•H2O, reflux, 6 h; (c) Pb(OAc)4, PhH, reflux; 2 h; 41% of 97b; 18 
h; 39% 97a; yield from 95; (d) 93, p-TsOH•H2O, CHCl3, rt; 70%; (e) SnCl4, CHCl3, rt, 16 h; 
84%; (f, g) Bromination followed by dehydrobromination; (h) 93, AlCl3, CH2Cl2, 0 ºC to rt, 72 h; 
16%; (C) Pb(OAc)4, PhH, gentle reflux; 2 h; (D) crude 97a/b, 93, p-TsOH•H2O, CHCl3, rt; 96 h; 
76% from 96; (E) TMSOTf, CH2Cl2/CH3NO2, 0 ºC to rt, 3 h; 73%
Note: C, D, E represent improvements as of 2014ref77
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This synthesis of enantioenriched nabilone, just as the original synthesis of racemic 20, 
leaves something to be desired — c’est-à-dire a high throughput synthesis void of heavy metal 
reagents. The use of SnCl4 for the annulation of 98 to (-)-20 introduces the same problem as the 
condensation/annulation of 92 with dimethylheptyl resorcinol during the synthesis of racemic 
nabilone, but unfortunately at the final step of the synthetic route (93, c; Scheme 2). This 
problem is exacerbated by the other heavy metal reagent employed to provide enantioenriched 
nabilone:  lead tetraacetate. Organic lead compounds, when exposed to air, are known to 
undergo fairly rapid degradation to form persistent inorganic lead compounds which can be 
difficult to remove during purification. Moreover, plumbum is designated as a Class 1 element, 
with no known biological function in humans, and the exposure to lead can cause adverse 
neurological, reproductive, developmental, immune, cardiovascular and renal health effects. The 
dangers associated with lead compounds have led to FDA allowable levels of exposure 100 
times more strict than those of tin.79 The strict guidelines for pharmaceuticals and the likelihood 
of lead contamination in samples of (-)-nabilone may be why Cesamet® is produced and 
administered as a racemate, as the production of (±)-20 does not require the use of the 
diacetates or lead during its synthesis.
Fortunately, the Eli Lilly synthesis of optically active nabilone has been repeatedly used 
over the last four decades, during which time chemists have addressed some issues 
encountered during the preparation of (-)-20. The state-of-the-art synthesis of (-)-nabilone was 
most recently used in 2014, during the production of 29 which features a lactone in the C ring 
and defines a new cannabinergic chemotype.77 The major modifications as of 2014 include:  (1) 
oxidation of 96 at the lowest temperature possible  to avoid the decomposition of the diacetates 
97; (2) use of crude 97 for condensation, which avoids the need for distillation; (3) supplanting 
SnCl4 with TMSOTf, to avoid the use of this heavy metal reagent (C, D, E; Scheme 3).74 These 
three major modifications resulted in an increase in the overall yield from 21% to 28% from 
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commercially available 94.77 Unfortunately the use of superstoichiometric lead tetraacetate is 
still necessary for the production of the diacetates, and no attempts to replace this toxic reagent 
have been reported. Furthermore, since the diacetates are required for an acceptable overall 
yield of (-)-nabilone, the unfortunate use of lead tetraacetate detracts from all the currently 
published syntheses of (-)-nabilone.
The straightforward and reproducible synthesis of (-)-nabilone, the groundbreaking 
activity and utility associated with its C-9 ketone, and the pharmaceutical success of its 
racemate, have encouraged chemists to derivatize the tricyclic cannabinoid core in hopes of 
discovering another molecule to add to the medical armamentarium. Moreover the skeleton of 
(-)-20 provides a cannabinoid framework well suited for late stage development of new 
cannabinergic chemotypes and functionalized inhibitors while ensuring that biological activity is 
retained. For these reasons, the strategy that was developed in 1977 by Archer and coworkers 
for the synthesis of optically active nabilone has arguably been the most widely applied for the 
preparation of classical, non-classical, and hybrid cannabinoids. This is where my work began.
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Chapter 2
The Total Synthesis of Ketocannabinoids Revisited 
 49
Work toward the targeted cannabinoid ligands featured in Figure 22 (Chapter 1) began 
as many synthetic projects do: Providing aid to a fellow graduate student on an analogous 
system. Assisting at this time Thanh Chi Ho for the synthesis of triflate 106, the author prepared 
diacetates 97, performed their condensation with persilylated phloroglucinol 101, and cyclized 
trihydroxyphenyl 102 to 105 (c, e, h; Scheme 4).
Originally outlined in 2010 by Dixon and coworkers for the late stage attachment of 
heteroadamantyl side chains,78 the synthesis to tricyclic intermediate 106 according to the 
process outlined in Scheme 4 is perhaps the most versatile route to cannabinoid analogues. 
The pathway to 106 represents a modification to the Eli Lilly synthesis of enantioenriched 
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aReagents and Conditions: (a) O3, CH3OH/CH2Cl2, -78 ºC, ii. Me2S, -78 ºC to rt; 89%; (b) 
isopropenyl acetate, p-TsOH•H2O, reflux, 6 h; (c) Pb(OAc)4, PhH, reflux, 2.5 h; 71% from 95; 
(d) Et3N, TMSCl, THF, 0 ºC to rt, 3 h (e) p-TsOH•H2O, CHCl3/Me2CO, 0 ºC to rt, 2 h; (f) Ac2O, 
Pyr, DMAP, CH2Cl2, rt, 12 h; chromatography; (g) KOH, CH3OH, 0 ºC, 2 h; 64% from 97 (h) 
TMSOTf, CH3NO2, 0 ºC, 2.5 h; 95%;  (i) PhNTf2, Et3N, CH2Cl2, rt, 14 h; 84%
Scheme 4: Synthesis of Advanced Intermediate Triflate 106a 
CH2 O OAc OAc
OAc
OAcAcO
+
OH
OHHO
OTMS
OTMSTMSO
HO
OH
O
OH
OH
OHHO
94 95 96 97a 97b
100 101 100
102
102
100
AcO
OAc
O
OAc
104
O
OH
O
OH O
OH
O
OTf
106105
a b c
d
e
f
h i
HO
OH
O
OH
102
103
g
nabilone (Scheme 3; Chapter 1), and takes advantage of the regioselective triflation of 105 that 
was developed in this group (i; Scheme 4). This synthesis was the first to combine functionality 
at C-9 with a C-3 triflate which enables late stage introduction of the side chain, as well as 
providing a synthetic handle for manipulations at the northern aliphatic region. 
Although useful, this route is both complicated and simplified by its aromatic component 
(100; Scheme 4). Phloroglucinol has limited solubility in CHCl3, the typical solvent previously 
used for the condensation of 97 with resorcinols. This problem was overcome by using 
persilylated phloroglucinol 101, as well as a mixed solvent system which included minimal 
amounts of acetone. Controlling the regiochemistry of the Friedel-Crafts addition was greatly 
simplified by using the C3 symmetric 101, as abnormal addition is not an issue (see 19-abn; 
Scheme 1; Chapter 1). However phloroglucinol is strongly activated toward electrophilic attack, 
allowing double addition to take place (see 19-dbl; Scheme 1; Chapter 1). This is suppressed 
by using a two-fold excess of the aromatic fragment. However, the presence of excess 100 at 
the end of the reaction is problematic, due to its similar chromatographic mobility with 102. This 
made it necessary to peracetylate the mixture of 100 and 102 so as separate the resulting 
acetates by chromatography (f; Scheme 4). This process unfortunately added two steps to the 
synthesis of 106, but does provide intermediate 104 which is appropriate for long term storage, 
in contrast to 102, which can oxidize quite rapidly to quinone derivatives when exposed to air 
(Scheme 4).78
Soon after work toward 106 began, lead tetraacetate, which is vital for the synthesis of 
97, came under short supply. Due to the reserve of oxidant becoming increasingly precious, 
work toward the synthesis of 106 was suspended. Thus a side project began, the stόchos of 
which was to devise a synthesis leading to optically active intermediates 107 — 109 that did not 
require the use of lead tetraacetate (Figure 23). The success of this project would expedite 
work toward targeted ligands 83 — 90 (Figure 22; Chapter 1), as well as abolish the toxic 
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heavy metal reagent that was a persistent relic of the oxidants available to chemists in 1977. 
Initial synthetic planning was guided by aspirations of an ideal synthesis which were enunciated 
by Hendrickson, Wender, and Gaich.80 These aspirations were further invigorated by the 
opportunity to contribute to a general synthetic route that uses innocuous reagents for the 
preparation of diverse and new cannabinoid ligands for the investigation of CB1 and CB2.
Since chemists began synthesizing cannabinoids, many dozens of synthetic routes have 
been described. The need for a synthetic handle at C-9 narrowed the scope of the literature 
reviewed to focus on routes that produced C-9 ketocannabinoids. The first synthesis of a 
ketocannabinoid related to 107 — 109 was described in 1966 by Fahrenholtz and coworkers.81a 
Fahrenholtz’s work utilized a ketocannabinoid as an intermediate to selectively produce racemic 
∆8- or ∆9-THC, and although noteworthy, this synthesis and its subsequent improvements81b are 
not enantioselective. Fahrenholtz’s work was repeated during the total synthesis of racemic 
nabilone by Archer, but the synthetic route was difficult to scale up, as was the separation of 
stereoisomers. Another strategy for the preparation of ketocannabinoids which expanded upon 
the Mechoulam synthesis of enantioenriched ∆9-THC was described during the total synthesis 
of nabilone (Scheme 1). By starting with (-)-verbenol, Archer provided an alternate method to 
(-)-nabilone, but this route suffered from a low yielding photolysis reaction and was complicated 
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Figure 23: Optically Active General Intermediates 107 - 109
Note: R1 = -OH, -H; R2 = -OH, -Alkyl, etc.
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by the late stage ozonolysis that introduced the C-9 ketone. The challenges encountered during 
the preparation of ketocannabinoids using the strategies of Fahrenholtz and Mechoulam were 
overcome by utilizing oxygenated terpenes, which led to the preferred routes previously outlined 
for the synthesis of (-)-nabilone (Scheme 2, 3; Chapter 1).75 
The strategies examined during the preparation of racemic and enantioenriched 
nabilone have been a valuable resource for subsequent syntheses of C-9 ketocannabinoids. 
Based on those strategies, and related work, two things are clear: 1. the introduction of the 
oxygen at C-9 should come early in the synthetic route and 2. asymmetry, without the use of 
asymmetry inducing ligands and/or catalysts, is most efficiently introduced by means of an 
enantioenriched terpene. This has led chemists to the common retrosynthetic disconnection of 
the C-10a — C-11 bond which fragments 107 into enantioenriched monoterpene A and 
aromatic fragment B (Figure 24).72
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Figure 24: Retrosynthetic Disconnection of Representative Ketocannabinoid 107
 and Common Oxygenated Terpenic Reaction Partners 
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This disconnection greatly simplifies the synthesis of bi- or tricyclic ketocannabinoids, 
and depending upon the C-3 alkyl group of the desired ligand, the aromatic fragment B can be 
chosen from a wide range of phenols (R1 = -H, R2 = -Alkyl) and resorcinols (R1 = -OH, R2 = -
Alkyl), or phloroglucinol (R1 = R2 = -OH; B; Figure 24). The achiral and planar reaction partner 
B has been combined with A, an oxygenated terpene, or terpene-derived partner such as the 
ones shown at the bottom of Figure 24. Any of the enantioenriched terpene-derived enones 110 
(R3 = Ac or TES or H) enables the synthesis of optically active tricyclic cannabinoids. Enone 110 
(R3 = Ac) was most conveniently prepared by Razdan starting from bicyclic nopinone (95) in two 
steps using BF3•OEt2 and zinc acetate (Zn(OAc)2) followed by a Saegusa oxidation as modified 
by Tsuji with allyl ethyl carbonate in the presence of Pd(OAc)2, DPPE, and Bu3SnOMe with an 
overall yield of 61%. The large γ substituent of 110 provides good facial selectivity during 
conjugate addition, and the products resulting from the condensation of 110 (R = Ac) with 
aromatic compounds are often further derivitized to provide ∆9-C-11 oxygenated cannabinoids. 
Similarly, silylated enone 110 (R3 = TES) or the unprotected tertiary alcohol 110 (R3 = H) provide 
comparable facial selectivity during the conjugate addition to its β-carbon, and can readily be 
cyclized to the classical tricyclic cannabinoid skeleton. However, the tertiary alcohol 110 (R3 = 
H) or its silylated counterpart 110 (R3 = TES) are prepared from 110 (R3 = Ac) in two or three 
additional steps with an overall yield of 44% or 37%, respectively. Enone 111a is most 
conveniently prepared from enantioenriched perillaldehyde, however this limits γ-substitution to 
isopropenyl, or isopropenyl derived alkyl substituents at R4. The isopropenyl group is large 
enough to direct conjugate addition to the natural trans configuration but n-alkyl substituents at 
this position lack the bulk to enforce stereoselectivity. The desire for a stereospecific 
condensation with 111a (R4 = n-alkyl) led Itagaki and coworkers to prepare the masked 
synthetic equivalent 111b for the preparation of nonclassical cannabinoids such as (-)-
CP-55,940 (Figure 24).72c While the caged bicycle 111b has potential to enable the expedient 
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synthesis of non-classical cannabinoids, its utility for the preparation of other cannabinoid 
classes presents a challenge, as the formation of the dihydrobenzopyran is not possible without 
functionality at C-6a (Figure 24). Moreover, while 111b can be prepared from commercially 
available 4-hydroxy cinnamate in six straightforward manipulations and provides nearly 
enantiopure 111b, the overall yield is 37%.71d The difficulty in procuring 110 or 111, preparing 
them enantioselectively, and their variable utility in the preparation of the bi- or tricyclic 
cannabinoid core have led to the choice of 97 or 99 for most enantioselective ketocannabinoid 
syntheses.
A distinct advantage of using either the diacetates 97 or enone 99 comes from the gem-
dimethyl substituent of the cyclobutane ring, which enforces complete facial selectivity during 
condensation to provide the general intermediate 108 (Figure 23). Moreover, subsequent 
intramolecular cyclobutane ring opening of 108 can be performed to furnish either the 
dihydrobenzopyran classical cannabinoid skeleton as seen in 109 or an isopropenyl group at 
C-6a, depicted by general intermediate 107, which allows functionalization of the non-classical 
bicyclic scaffold, all the while maintaining the R absolute stereochemistry at C-6a (Figure 23). 
Additionally, the synthesis of either the diacetates or apoverbenone from nopinone is more 
concise than the syntheses of 110 or 111.
Although both apoverbenone (99) and the diacetates (97) have been used to produce 
C-9 ketocannabinoids, the use of 99 as a terpenic unit has often been hampered by its lack of 
reactivity.72,74,75 A synthetic equivalent of 97 that retains its reactivity and precludes the use of 
lead tetraacetate would solve the problem of using this toxic reagent, however, devising a three 
step route to an enantioenriched equivalent of 97, which is more reactive than 99, and leads to 
stereospecific condensation was a challenge. An alternative chiral, non-racemic equivalent of 97 
that was not derived from 97 or enone 99 was difficult to imagine which prompted a closer look 
at the previous syntheses of ketocannabinoids.
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As described for the synthesis of optically active nabilone, 99 was combined with 
resorcinol 93 by the action of aluminum chloride (b; Scheme 5). Although AlCl3 is an extremely 
reactive Lewis acid, and even though the yield of this step was minuscule, this experiment 
provided a precedent for a successful Lewis acid mediated conjugate addition to apoverbenone. 
Because low reactivity has been associated with apoverbenone, Lewis acids have always been 
used to activate it toward conjugate addition during ketocanabinoid syntheses. Moreover, the 
1,4-addition of resorcinols with non-bulky C-5 side chains to apoverbenone has required higher 
order aryl cuprates as well as Lewis acids to obtain high yields of intermediate cannabinoids 
(113; a; Scheme 5).82c Scouring the literature for other perhaps less cumbersome methods for 
conjugate addition to 99 provided two published reports, only one of which had been utilized for 
the synthesis of cannabinoids (c, d; Scheme 5).
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Scheme 5: Representative Examples of Conjugate Addition to Apoverbenonea
aReagents and Conditions: (a) n-BuLi, 112A or 112B, THF, LiCuCN(Imidazole); to 
cuprate add 1/1 99/BF3•Et2O, THF, -78 ºC, 66% of 113A, 55% of 113B; (b) 93, AlCl3, 
CH2Cl2, 0 ºC to rt, 72 h; 16%; (c) 114, cathodic electrolysis conditions, 0.02-0.05 F/mol; 
unreported yield; (d) 116, In0, TMSCl, THF, 0.5 h, rt; unreported yield.
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Diester 117 was used by Moore and coworkers for the production of heteroaromatic and 
pyridyl non-classical cannabinoids ligands.82b,c Although this method is presumably well suited 
for the preparation of these particular ligands it uses exotic indium metal to perform the 1,4-
addition and the yield associated with this method is not mentioned. Similarly the yield of the 
electrochemically82f catalyzed 1,4-addition to 99 was not reported. The scarceness of published 
examples as well as the elaborate experimental conditions necessary for successful conjugate 
addition to 99 further reinforced the impression that apoverbenone is a poor Michael acceptor.
It was curious that conjugate addition to 99 appeared to be such a challenge for 
chemists, as all manner of enones are widely used as Michael acceptors. Given the similarity 
between 97 and 99 a nucleophilic conjugate addition to apoverbenone should be possible under 
similar conditions. Because 97 easily decomposes to apoverbenone, the presence of 99 in 
reaction mixtures was thought to be responsible for the low yields and long reaction times of 
Brønsted acid catalyzed Michael additions to 97.72a,74,75,77 However, the precedent of aluminum 
chloride which sufficiently polarized 99 for 1,4-addition, prompted us to investigate a wider panel 
of Lewis acids, including ones that were unknown in the 1970s, but which could similarly 
activate apoverbenone. Before Lewis acids could be screened however, a more convenient 
route to apoverbenone was necessary.
Contemporary procedures that furnish apoverbenone start with ketone 95 and are 
addition-elimination methods that take advantage of the fact that nopinone can only enolize to 
form a single enolate that does not violate Bredt’s Rule. Although useful, the addition is often 
non-selective, and provides an unequal mixture of diastereomers in favor of equatorial α-
substitution. These diastereomers are not separated but isomerized in a separated step to 
afford the axial α-substituent which is antiperiplanar to one of the β-hydrogen atoms to facilitate 
elimination. Additionally, noxious or toxic reagents, two or more steps, and high temperatures 
are required to produce enone 99 via the reported pathways.83
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The need for 99 with high optical purity led Grimshaw and Grimshaw to extensively 
study and improve upon the known methods for the preparation of apoverbenone in 1972. Their 
work has been replicated a number times in the last forty years and involves the bromination 
and dehydrobromination of nopinone to obtain 99 in 70% overall yield (Route 1; Scheme 6).84a 
Purification and recrystallization of intermediate α-bromoketone (118-ax, X = Br) prior to 
dehydrobromination provided 99 with high optical purity following elimination. This route, 
although fairly straightforward is encumbered by the need to isomerize 118-eq to 118-ax (X = 
Br) with alumina so as to facilitate elimination, and by the variability of the radical bromination 
which can produce between 58% and 81% yield of 118 (X = Br). This inconsistency in yield is 
presumably due to the formation of α,α-dibromide compounds which often lead to the 
decomposition of 118 (X = Br).83,85
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Scheme 6: Classical Conversions of Nopinone to Apoverbenonea
aReagents and Conditions: Route 1: (a) NBS, CCl4, benzoyl peroxide, reflux, 3 h; 118 
(X = -Br); (b) Al2O3; 58% two steps; (c)118-ax (X = -Br), Li2CO3, LiBr, DMSO, 150 ºC, 60 
h; 74%; Route 2: (a) (PhSe)2, SeO2, MsOH; 87% of 118-ax (X = -SePh); (c) 7.5% H2O2, 
then pyridine, CH2Cl2; 70%; Route 3: (a) LDA, PhSSO2Ph, THF; 97%; 85:15 118-eq:
118-ax (X = -SPh); (d) Using purified 118-eq or 118-ax or 118 (X = -SPh), m-CPBA, 
CH2Cl2; 99% 2:1 diastereomeric sulfoxides (e) K2CO3, PhMe, 120 ºC, 4 h; 93%.
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In 1993 Kato and coworkers described an alternate route to 99 using an addition-
elimination approach. Phenylselenenylation of nopinone 95, followed by selenoxide 
fragmentation provides apoverbenone in 63% overall yield (Route 2; Scheme 6).86 The use of 
toxic and expensive selenenyl compounds for this transformation was unattractive to us in the 
context of the broader synthetic revision that was underway. Kato, noted that this reagent choice 
was not optimal, and disclosed a further improvement for the preparation of 99 five years later. 
This route proceeded by way of sulfenylation, isomerization, oxidation, and dehydrosulfenylation 
of nopinone to furnish 99 in 89% overall yield (Route 3; Scheme 6). Although a competing 
Pummerer rearrangement to form 120 was reported during dehydrosulfenylation, this could be 
avoided by proper purification of intermediate 119 and the reagents required for its final 
transformation to apoverbenone.83 While these addition-elimination methods have merit, the 
problems associated with them discouraged their use. 
Methods to dehydrogenate aliphatic ketones to enones in a single step, either by the use 
of stoichiometric oxidants, or catalytically, have been developed extensively in the years 
following Kato’s work, yet their application to ketone 95 had not been described.87 Moreover, 
ever since Nicolaou and coworkers in 2002 described the use of o-iodoxybenzoic acid (IBX, 
122; Figure 25) as an oxidant that can be tuned to convert aliphatic ketones either to enones or 
dienones, IBX has been commonly used for desaturating ketones. Additionally, IBX is cheap, 
easily handled, and effective under mild conditions and could lead to 99 directly from nopinone 
in a single step without the need for heavy metal reagents. Therefore, IBX was our first choice 
for the attempted one step transformation of 95 to 99.87
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After extensive efforts we were unable to perform dehydrogenation of nopinone using a 
sub-stoichiometic loading of IBX with Oxone® as the stoichiometric oxidant. Complete 
dehydrogenation of nopinone to apoverbenone using an IBX and Oxone® system was only 
achieved through the use of four equivalents of 122, and although this represented a one step 
procedure, it provided an unacceptable 20% yield of 99 (a; Scheme 7). It is unclear where the 
material loss occurred during the dehydrogenation with IBX. Initially it was suspected that the 
volatility of 99 led to the decreased yield, but this was discounted when following 
dehydrogenation, purified 99 was concentrated with a gentle stream of nitrogen to provide 
similar yields to those obtained when concentration took place under reduced pressure. 
Suspecting that decomposition of 95 and/or 99 was taking place as a result of the use of 
superstoichiometric IBX and Oxone®, we looked for a more reactive IV reagent which could be 
used catalytically for this dehydrogenation.
Recently o-iodoxybenzesulfonic acid (IBS, 124; Figure 25), has been described by 
Ishihara and coworkers as a more reactive alternative to o-iodoxybenzoic acid.88 In an attempt 
to overcome the sluggish dehydrogenation to apoverbenone by IBX, 124 was employed for the 
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Figure 25: Common Hypervalent Iodide Species 
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transformation of 95 to 99. This was also not successful, and full conversion to 99 was not 
accomplished during our screening of this reagent (b; Scheme 7). This result was a stark 
contrast to the positive control, which provided cyclohexenone from cyclohexanone in 89% yield 
when the latter was treated with 5 mol% IBS and stoichiometric Oxone® in nitromethane.
Reported examples of the dehydrogenation of ketones that use hypervalent iodine 
reagents have all been on substrates that are relatively more conformationally flexible and less 
hindered than ketone 95. Mechanistically, the dehydrogenation of nopinone using IBX (or IBS) 
has been proposed to proceed through either an ionic or single election transfer (SET) pathway 
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Scheme 7: Proposed Mechanism for the Dehydrogenation of Nopinone Using IBX,
 and One Step Dehydrogenation to Apoverbenone Using IV Speciesa
aReagents and Conditions: (a) IBX, DMSO, 80 ºC, 20%; (b) IBS, Oxone, 
CH3NO2, 80 ºC, 48 h, 80% conversion 
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beginning with the complexation of the enol tautomer of 95 followed by proton transfer (Scheme 
7). Additionally, during the oxidation of alcohols with IBX (postulated as an ionic mechanism), 
the rate-limiting step has been shown to be the hypervalent twisting of intermediate IBX-
substrate complexes. This twisting is a coordinated motion of intermediates such as II and III 
driven by the necessity to generate the more stable and planar form of the byproduct IBA, 121, 
which is obtained after a successful oxidation (Scheme 7).87h Although the analogous study of 
the rate-limiting step during the dehydrogenation of ketones has yet to be reported, it follows 
that the bridged dimethyl cyclobutane ring of 95 may severely hinder the necessary rotation of 
intermediates II or III, resulting in the unsatisfactory yields.
An unfortunate and complicating aspect of the one step dehydrogenation of 95 to 99 
stems from the similarity of the starting material’s physical properties with those of 
apoverbenone. The chromatographic mobilities of 95 and 99 are so similar that a one step 
procedure can't be monitored by thin layer chromatography (TLC), requiring the inconvenient 
use of 1H NMR, MS, or IR to assess its progress. Furthermore, if the dehydrogenation was 
incomplete, the isolation enone 99 by flash chromatography or distillation provided negligible 
separation — entraining ketone starting material within the product. The failure of the iodine 
reagents to produce 99 in acceptable yield led us to examine two step procedures for the 
oxidation of 95.
The first thought for a two step process was a Saegusa-Ito oxidation that proceeded 
through enol ester or a trialkylsilyl enol ether of 95 (125; Scheme 8). Modifications to the 
standard Saegusa oxidation by Tsuji could be applied to acetate 125 (R = Ac; Scheme 8; also 
96; Scheme 4). However, this modification requires the use of tributyltin methoxide to provide 
the tin enolate intermediate (IV, R = SnBu3), which is necessary for transmetallation with a π-
allylpalladium complex generated in situ to afford intermediate V (L = allyl) which subsequently 
undergoes the desired β-hydride elimination (Scheme 8). Even though this method would use 
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the mono-acetate 96 that had been prepared in our group, the application of a toxic tin reagent 
was unattractive. An alternative modification, also by Tsuji, employs an allyl enol carbonate 
(125; R = CO2CH2CHCH2) to generate the same intermediate V (L = allyl) without the use of 
tributyltin methoxide. This method has been used to prepare enones in good yields, and 125 (R 
= CO2CH2CHCH2) would presumably be isolable and possess much different chromatographic 
mobility than that of 95 or 99, allowing for a straightforward stepwise oxidation. 
Treatment of 95 with LDA followed by allyl chloroformate provided 125 (R = 
CO2CH2CHCH2) in 92% yield after chromatography. However, boiling 125 (R = CO2CH2CHCH2) 
in acetonitrile with stoichiometric palladium acetate and 1,2-bis-(diphenylphosphino)ethane 
(dppe) produced no observable enone 99, and the majority of allyl enol carbonate was 
recovered from the reaction unchanged. This failure was peculiar, given the substrate scope 
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Scheme 8: Saegusa-Ito Oxidation of Nopinonea
aReagents and Conditions: (a) see text; (b) LDA, TMSCl, -78 ºC to 0 ºC, 1 h; [provides crude 
125 (R = TMS)] (c) cat. Pd(OAc)2, DMSO, O2, rt, 36 h; 85% from 95
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presented by Tsuji and success of the positive control, which afforded cyclohexenone in 76% 
overall yield from cyclohexanone. However, recovery of allyl enol carbonate 125 (R = 
CO2CH2CHCH2) was not altogether unexpected following the unsuccessful dehydrogenation of 
95 using iodine reagents. The recovery of 125 (R = CO2CH2CHCH2) after its attempted 
oxidation suggested that intermediate IV was forming either reversibly or not at all, and that 
under these conditions the coordination of palladium to provide intermediate V was not 
occurring (Scheme 8). This led us to trap the enolate of 95 as a silyl enol ether (125; R = TMS), 
which  has been shown to form oxa-π-allylpalladium complexes such as V (L = OAc) under mild 
conditions, which following dehydrosilylation affords enones in excellent yields.89
Silyl enol ether 125 (R = TMS) was prepared by the treatment of nopinone with LDA 
followed by trimethylsilyl chloride in nearly quantitative yield (a; Scheme 8). In order to avoid 
heating 125 (R = TMS) and aspiring to use only catalytic palladium, the modifications to the 
Saegusa reaction that were described by Larock and coworkers were applied.89c Replication of 
Larock’s method by treatment of 125 (R = TMS) with palladium acetate in dimethylsulfoxide 
under an atmosphere of oxygen at ambient temperature provided 99. The amount of Pd(OAc)2 
could be decreased to 2.5 mol%, however this led to the recovery of ca. 10% of unreacted 95 as 
judged by 1H NMR. For the most cost effective dehydrosilylation of 125 (R = TMS) a catalyst 
loading of 10 mol% was determined to be optimal (b; Scheme 8). Under these conditions 
apoverbenone was produced in 85% yield over two steps with minimal recovery of nopinone 
(~4% as judged by 1H NMR). Additionally, the optical purity of 99 obtained through the Saegusa-
Ito oxidation was comparable to that obtained by Grimshaw’s procedure, with the discrepancy 
presumably cause by both the optical purity of our commercially sourced (-)-β-pinene (96% ee) 
as well as unreacted 95 which inversely bends polarized light ([α]20D +311.0° (c 2.4, CHCl3) [lit. 
[α]25D +319° (c 2.4% in CHCl3)]).84 Application of the Saegusa-Ito oxidation did not reduce the 
total number of steps to 99, however, this method is high yielding, mild, catalytic, and easily 
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monitored by TLC. Moreover, 99 is formed from intermediate 125 (R = TMS) without the need 
for purification, isomerization, sulfoxide formation (as in the dehydrosulfenylation which affords 
119) or extreme heat, superseding the previously described processes which provide 
apoverbenone.
With apoverbenone in hand, various methods were screened to determine its potential 
as a Michael acceptor. To improve the likelihood of success, initial attempts at conjugate 
addition employed the highly activated, electron rich nucleophile phloroglucinol (100). 
Additionally, the first Lewis acids screened were scandium triflate (Sc(OTf)3) and ytterbium 
triflate (Yb(OTf)3), which were chosen for their non-nucleophilic counter ion. Unfortunately the 
mixture of 99, 100, and either Lewis acid in a variety of solvents and at a number of different 
temperatures did not result in conjugate addition (Scheme 9).90 Conjugate addition of 
phloroglucinol to enones has been shown to be catalyzed under basic conditions, however, 
subjecting 100 to sodium hydride (NaH) in THF followed by the introduction of apoverbenone to 
the reaction mixture was unsuccessful for the preparation of 102.
The permethyl ether of phloroglucinol (126) has also been used for the conjugate 
addition to enones, but this nucleophile has required the use of the unusual amphoteric Lewis 
acid-Lewis base, vanadyl triflate (VO(OTf)2) to afford Michael adducts.91 Chen and coworkers 
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Scheme 9: Initial Attempts to Prepare 102 Through The Michael Addition of 
Apoverbenone
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describe the Friedel-Crafts type addition of 126 to cyclohexenone in high yield using VO(OTf)2 
and postulate that this oxometallic catalyst behaves as an strong Lewis acid at its vanadium 
center, which is amplified by the electron withdrawing counter ions to activate enones for 
conjugate addition. Moreover, the polarizability of the oxovanadium double bond allows the 
oxygen to activate nucleophiles by behaving as a Lewis base, resulting in a push-pull 
mechanism to afford the desired 1,4-addition. 
Although the use of the permethyl ether of phloroglucinol is less attractive than 
persilylated phloroglucinol 101, due to the less practical cleavage of -OCH3 compared to -
OTMS, the exceptional 91% yield of its 1,4-addition to cyclohexenone urged its use. Preparation 
of VO(OTf)2 and suspending it with 126 and 99 in dichloromethane (DCM) resulted in the 
complete consumption of apoverbenone while producing 127 in 50% yield (b; Scheme 10). 
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Scheme 10: Vanadyl Triflate Catalyzed Michael Addition of Phloroglucinola
aReagents and Conditions: (a) K2CO3, DMF, MeI, rt, 4 h; 80%; (b) cat. VO(OTf)2, 
CH2Cl2, rt; 50% from 99; (c) Et3N, TMSCl, 0 ºC to rt, 3 h; (d) cat. VO(OTf)2, CH2Cl2, rt, 
40 h; (e) Ac2O, Pyr, DMAP, CH2Cl2, rt, 12 h; 63% from 99
Spurred by this encouraging result, the vanadyl triflate catalyzed Michael addition of persilylated 
phloroglucinol 101 to apoverbenone was carried out (d; Scheme 10). Michael addition was 
successful using the amphoteric Lewis acid. After exchanging the trimethylsilyl for acetyl groups, 
triacetate 104 was provided in 63% yield over two steps, a five percent decrease in yield from 
the analogous condensation and peracetylation depicted in Scheme 4 (e, f). Comparing this 
result with Dixon’s route to triacetate intermediate 104 from 95, the four steps using either 
diacetates 97 and p-TsOH, or apoverbenone and VO(OTf)2 followed by acetylation, provide 104 
in 48% or 54% overall yield, respectively. 
This new method which provides triacetate 104 via vanadyl triflate catalyzed Michael 
addition demonstrates that a high yielding synthesis of enantioenriched ketocannabinoids 
107-109 can be performed without having to proceed through diacetates 97 and hence without 
the toxic lead tetraacetate. Moreover, in the presence of vanadyl triflate (b, d; Scheme 10), 
apoverbenone was shown to behave as a competent  Michael acceptor.
Impressed by the reactivity of apoverbenone in the presence of catalytic vanadyl triflate, 
we attempted to perform a Michael addition using a less electron rich aromatic system, the C-5 
substituted resorcinol 93 (Scheme 11). To ensure solubility in DCM, dimethylheptyl resorcinol 
was silylated and charged to a vessel containing Michael acceptor 99 and the vanadium 
catalyst. These conditions led to a heterogeneous reaction mixture that provided Michael adduct 
98 in 49% yield after chromatography. (b; Scheme 11). Because resorcinols are less electron 
rich and therefore less nucleophilic than phloroglucinol this reaction did not go to completion 
after four days at ambient temperature. The rather low yield obtained after the addition of 128 to 
apoverbenone was discouraging. However, the yield could be improved by exploiting the 
regiospecificity exhibited by dimethylheptyl resorcinol during conjugate addition as well as the 
thermal stability of 99, a combination of features not found during the addition of 93 to the 
diacetates (97) or the addition of phloroglucinol to apoverbenone (99).
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Apoverbenone, unlike the diacetates, 97, can be heated above 60 ºC for prolonged 
periods of time without decomposition. The thermal stability of apoverbenone allows any 
Michael addition to 99 to be driven to completion by heating the reaction mixture. Also, the 
tertiary benzylic alkyl group of dimethylheptyl resorcinol is able to block ortho-substitution — 
suppressing the formation of abnormal and double addition adducts even at elevated 
temperatures. Furthermore, because the addition of 93 or 128 takes place regioselectively, a 
slight excess of enone 99 was found to be advantageous to drive the reaction to completion 
instead of an excess of 128. The use of excess 99 also simplified the purification of 98 because 
of the complete consumption of 93, and the large difference in chromatographic mobility of the 
Michael adduct and 99. Taking all this into account, DCM was replaced by the higher boiling 1,2-
dichloroethane (DCE) and the vanadyl triflate catalyzed Michael addition of 128 to 99 was 
repeated (c; Scheme 11). These adjustments reduced the reaction time by 25% and bolstered 
the yield of 98 to 73%. While monitoring the reaction by thin layer chromatography (TLC) it was 
noted that at elevated temperature, rapid desilylation of 128 took place. Critically, however, this 
did not impede the production of 98, suggesting the use of free dimethylheptyl resorcinol 93 in 
this reaction. Surprisingly, 93 was quite soluble in warm DCE and a day of heating with 99 and 
the vanadium catalyst rendered the reaction mixture a slurry, characteristic of the formation of 
98 (d; Scheme 12). Circumventing the unstable bis-silyl ether 128 not only simplified the 
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Scheme 11: Vanadyl Triflate Catalyzed Michael Addition of Dimethylheptyl Resorcinola
aReagents and Conditions: (a) Et3N, TMSCl, 0 ºC, 0.5 h; (b) cat. 
VO(OTf)2, CH2Cl2, rt, 48 h; 49% yield; (c) cat. VO(OTf)2, ClCH2CH2Cl, 
60 ºC, 36 h; 73%
experimental effort to produce 98, but eliminated complications of the vanadyl catalyzed Michael 
addition that were encountered if crude 128 was contaminated with any reagents used for its 
production. 
Optimization of the Michael addition of free resorcinol 93 to apoverbenone showed that 
even 1 mol% of vanadyl triflate with heating in DCE for two days was sufficient to produce 83% 
yield of Michael adduct 98 following chromatography (d; Scheme 12). A decrease in the 
reaction time was achieved with an increase in catalyst loading (10 mol%, 24 hours); notably, 
when the reaction mixture was heated for a day without the addition of vanadyl triflate, 93 and 
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Scheme 12: Vanadyl Triflate Catalyzed Michael Addition 
Applied to The Total Synthesis of (-)-Nabilonea
aReagents and Conditions: (a) O3, CH3OH/CH2Cl2, -78 ºC, ii. Me2S, -78 ºC to rt; 89%; (b) 
LDA, TMSCl,-78 ºC to 0 ºC, 0.5 h; (c) cat. Pd(OAc)2, DMSO, O2; 85% over 2 steps; (d) cat. 
VO(OTf)2, DCE, 60 ºC, 24 h; 83%; (e) TMSOTf, CH2Cl2/CH3NO2, 0 ºC to rt, 3 h; 73% (f) 
Conditions d followed by e without isolation of 98; 60% over 2 steps (D) DCE, 60 ºC, 10 h; 
(F) TMSOTf, CH2Cl2/CH3NO2, 0 ºC to rt, 3 h
Note: Conditions D and F are controls, see text
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99 were recovered unchanged (D; Scheme 12). The mild anhydrous conditions of this reaction 
make it possible to introduce TMSOTf after the Michael addition has proceeded to completion 
so as to catalyze the formation of the tricyclic cannabinoid skeleton in a single operation. 
Charging a reaction vessel with vanadyl triflate, 99 and 93 followed by TMSOTf after the 
complete consumption of 93 provided (-)-20 in 60% overall yield after chromatography (f; 
Scheme 12). The vanadyl triflate catalyzed one pot procedure to (-)-nabilone represents a great 
improvement over the one pot addition of 93 to 99 described by Archer, and increases the yield 
nearly four-fold (3.75x), bringing the overall yield of this synthesis to 49% from 94.
 To determine whether trimethylsilyl triflate could catalyze the Michael addition of 93 to 
apoverbenone as well as the cyclobutane ring opening to produced (-)-20, TMSOTf was used in 
place of vanadyl triflate (F; Scheme 12). These reaction conditions led to the complete 
decomposition of enone 99 within three hours while leaving dimethylheptyl resorcinol 
unchanged. By analysis of the crude reaction mixture by HRMS and by comparison of HPLC 
retention times with an authentic sample the presence of trace amounts of (-)-nabilone was 
confirmed.
Although this improved synthesis of optically active nabilone avoids the use of the toxic 
heavy metal reagents employed during previous syntheses, it relies upon vanadyl triflate. 
Vanadium (V0) is a genotoxin but is not mutagenic and is designated as a Class 2A element, 
having toxicity on par with nickel and cobalt, with an essential biological role in humans not yet 
established. The primary targets for vanadium toxicity are the GI tract, cardiovascular and 
hematological systems, however, oral administration of ammonium vanadyl tartrate or vanadyl 
sulfate (VIV) to humans was conducted during a study and no significant alterations to these 
physiological systems was found.79 Moreover its catalytic role during the synthesis of (-)-
nabilone and simple chromatographic separation from 98 or (-)-20 justify it’s use.
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The unexpectedly high reactivity of apoverbenone as a Michael acceptor that was 
revealed during the execution of the preceding work prompted a critical reexamination of the 
relevant literature. The following four points are worth reiteration:  (1) “Successful condensation 
of diacetates with dimethylheptyl resorcinol is achieved at room temperature with p-
toluenesulfonic acid in chloroform after three days”,75,77 (2) “Apoverbenone does not react under 
[condensation] conditions”,72a,74 (3) “[apoverbenone] formation is one of the reasons for the 
observed low yield of [the condensation] reaction”,74 (4) “In the absence of [resorcinol], the 
mixture of diacetates 97 are completely converted to apoverbenone 99 in about 1.5 hours in the 
presence of p-toluenesulfonic acid”.74 
Claims 1, 2, and 3 are in agreement, however claim 4, when read in conjunction with the 
others aroused skepticism. Why would the decomposition of 97 to 99 be somehow slowed or 
inhibited by the addition of resorcinol to the reaction mixture? And how do the diacetates survive 
three days of acid exposure in claim 1, but decompose within hours according to claim 4? 
Suspecting that apoverbenone was the active electrophile during previously reported 
Brønsted acid catalyzed condensations with resorcinols and phloroglucinol, 99 was combined 
with stoichiometric p-TsOH and excess persilylated phloroglucinol 101 in a mixed solvent of 
chloroform and acetone (Scheme 13). The reaction mixture instantly became homogenous and 
golden in color, but quickly turned milky and heterogeneous, presumably due to the acid 
catalyzed desilylation of 101 that leads to insoluble phloroglucinol. The heterogenous mixture 
was allowed to stir and remarkably after seven hours apoverbenone was completely consumed 
as judged by TLC! Examination of the crude reaction mixture by 1H NMR revealed that 102 was 
the major product, which was isolated in 32% yield after column chromatography on silica gel 
(Scheme 13). Because the p-TsOH led to the rapid cleavage of the silyl groups of 101, free 
phloroglucinol was subsequently used at the outset of this reaction. This drastically reduced the 
reaction time to two hours, however, the free phenolic groups increased the nucleophilicity of 
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the aromatic starting material, and produced large amounts of 102-dbl (Scheme 13). The 
problematic bis-addition was suppressed by using an addition funnel with metering stopcock to 
slowly introduce a dilute solution of 99 to a mixture of phloroglucinol and p-TsOH in acetone. 
Additionally, dissolving 99 in dichloroethane instead of chloroform provided exclusively 102 in a 
completely homogeneous reaction mixture at a much higher concentration than the one 
previously used (0.1M vs. 0.03M). Moreover, with adequately slow addition of 99, bis-addition 
can be avoided even when fewer than 2 equivalents of 100 are used for this reaction.
Further improvement to this route was achieved through a simplified isolation procedure 
for Michael adduct 102. Consultation of Armarego and Chai’s Purification of Laboratory 
Chemicals revealed that water is the preferred solvent for the recrystallization of phloroglucinol, 
prompting the use of hot water during extraction, or (for large reactions) a continuous extractor 
to separate crude 102 from free phloroglucinol (Scheme 13).92 This trivially simple exploitation 
of physical properties allowed 102 to be isolated essentially pure in ~70% yield following the 
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Scheme 13: Michael Addition of Phloroglucinol to Apoverbenone 
Catalyzed by p-Toluenesulfonic Acida
aReagents and Conditions: (a) Et3N, TMSCl, 0 ºC to rt, 3 h; (b) p-TsOH, 1:4 
acetone:DCE (0.1M), rt; ~70% from 100 (c) Ac2O, Pyr, DMAP, CH2Cl2, rt, 12 h; 57% 
from 100 (d) TMSOTf, CH3NO2, 0 ºC, 2.5 h; 54% from 100 (2 steps).
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revised extraction procedure. Unfortunately, 102 rapidly oxidizes in air which led to variable 
yields of purified product, and it was found to be convenient to peracetylate 102 to 104 for 
storage. This triacetate could be consistently provided in 57% yield over two steps — a 10% 
increase to the overall yield from 95 while avoiding the persilylation of 100 (b, c; Scheme 13). 
Alternatively, 102 could be cyclized to the more stable 105 by the methods described by Dixon 
in 54% yield over two steps — a meager 8% improvement to the overall yield from nopinone but 
in three fewer operations then previously reported (Scheme 4; 8; 13).78 
That Brønsted acid catalyzed Michael addition of phloroglucinol to apoverbenone should 
occur is not surprising, however, we found no precedent for such a straightforward process for 
the synthesis of tricyclic ketocannabinoids. The optimized solvent system of 1:4 acetone:DCE 
dissolved unprotected phloroglucinol and obviated the cumbersome persilylation step. This, 
combined with the simple hot water extraction of 100 from Michael adduct 102, vastly reduced 
the experimental effort needed to provide triacetate 104 or tricyclic 105. Moreover, the 
improvements described above resolved a major experimental complication of this route which 
required peracetylation and two additional steps to obtain purified 102 and subsequently 105 
while achieving an increase in the overall yield (Schemes 4; 8; 13).78 
Large scale preparation of 102 by the method described above is somewhat impractical 
due to the lengthy reaction times which are required to ensure the addition of apoverbenone is 
adequately slow so as to avoid formation of 102-dbl. This reaction sequence which may be 
further optimized by using a milder Brønsted acid to discourage the formation of 102-dbl while 
still polarizing 99 toward conjugate addition, however, the screening of alternative acids was not 
completed because the synthesis of 102 was ancillary to the desired conjugate addition of the 
less nucleophilic 93 to 99, which would require a strongly polarizing Brønsted acid to provide 98 
and subsequently (-)-nabilone.
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Ventre à terre the Brønsted acid catalyzed addition of a less nucleophilic aromatic ring 
was examined. p-Toluenesulfonic acid was added to a solution of apoverbenone and 
dimethylheptyl resorcinol in dichloroethane. After two hours of heating, apoverbenone was 
completely consumed and examination of the crude reaction mixture by 1H NMR showed 
decomposed enone as well as a 2.5:1 ratio of Michael adduct to nabilone. This direct, Brønsted 
acid catalyzed Michael addition of resorcinols to apoverbenone, which had been overlooked for 
close to four decades was optimized in short order, and can now be applied to expedited 
syntheses of bi- or tricyclic cannabinoids. The details of this effort are described in what follows.
During the optimization of this Michael reaction it was found that the undesired p-TsOH 
catalyzed intramolecular cyclobutane ring opening could be suppressed through the use of 
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Scheme 14: p-Toluenesulfonic Acid Catalyzed Michael Addition 
of Dimethylheptyl Resorcinol to Apoverbenone Applied to The Total Synthesis of Nabilonea
aReagents and Conditions: (a) O3, CH3OH/CH2Cl2, -78 ºC, ii. Me2S, -78 ºC to rt; 89%; (b) LDA, 
TMSCl, -78 ºC to 0 ºC, 0.5 h; (c) cat. Pd(OAc)2, DMSO, O2; 85% over 2 steps; (d) cat. p-
TsOH, DCE, 60 ºC, 18 h; 94%; (e) TMSOTf, CH2Cl2/CH3NO2, 0 ºC to rt, 3 h; 87%
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catalytic acid, and/or performing the reaction at a lower concentration, both of which increase 
the reaction time of the bimolecular addition but selectively produce 98. Reducing the load of 
acid also slowed the competitive decomposition of 99. The use of ambient or inert atmosphere 
had a drastic effect on the time course of this reaction, but little to no effect on the yield of 98. 
Under nitrogen or air, the Brønsted acid catalyzed Michael addition was complete in 20 hours or 
108 hours, providing 82% or 83% of 98, respectively. Reactions performed open to air did 
become red as time passed, indicative of quinone formation; however, this byproduct was in 
such low concentrations that its detection and isolation were challenging and the effort to do so 
was abandoned. Although a one pot procedure to (-)-nabilone by addition of TMSOTf to crude 
98 was possible, it was found advantageous to isolate the Michael adduct. This phenolic 
intermediate has limited solubility in DCE, in contrast to its terpenic and aromatic starting 
materials. Rinsing 98 with cold DCE on a fine fritted glass filter attached to a rotary vane pump 
proved superior to purification by chromatography. The isolation of 98 by filtration increased the 
isolated yield of this Michael addition to 94% from the 83% obtained following column 
chromatography (d; Scheme 14). Unfortunately, this technique could not be applied to the 
vanadyl catalyzed Michael addition because unlike p-TsOH, VO(OTf)2 is insoluble in DCE and 
would require chromatography to separate it from 98. However, this filtration protocol may be 
applicable to the isolation of other phenolic cannabinoids in high enantiopurity, as the highly 
crystalline nature of resorcinol intermediates such as 98 has been previously noted.82 
The chemical purity of the filtered crystals was determined to be >99% by LCMS and 
HPLC with an evaporative light scattering detector (ELSD), and exhibited a sharp melting point 
(174.2—175.3 ºC, [lit.54c mp 174—176 ºC]) immediately following filtration. For comparison, 98 
obtained directly from column chromatography melted at 169.7—173.5 ºC and was only 89% 
pure, as determined by LCMS (254 nm), requiring recrystallization to reach analytical purity. 
Additionally, the use of highly pure Michael adduct for the intramolecular cyclobutane ring 
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opening increases the yield of this step to 87%, compared with the typical 73% yield of (-)-20 
obtained by using chromatographically purified 98 (e, Scheme 14).
Surprisingly, the brilliant white crystalline Michael adduct obtained by filtration rotates the 
plane of polarization of polarized light to a greater degree than the samples prepared by Archer 
([α]20D +83.6° (c 1.0, CHCl3) [lit.75a [α]20D +55.8° (c 1.0, CHCl3)]). Subsequent cyclization resulted 
in (-)-nabilone with a specific rotation greater than any yet reported ([α]20D -62.5º (c 1.0, CHCl3) 
[lit.75a [α]20D -55.7° (c 1.0, CHCl3)]). The discrepancy between these data and those reported in 
the literature required further investigation, the details of which are described in what follows.
Archer and coworkers’ synthesis of (-)-nabilone starting from enantioenriched (-)-trans-
verbenol exhibited the highest optical purity (-55.7º (c 1.0, CHCl3)) of all the routes described in 
1977,75e however, this monoterpene was prepared according to Whitham’s procedure from (-)-α-
pinene and exhibited a specific rotation of -118º (c 0.96, MeOH).75a,c Although the specific 
rotation reported by Archer was recorded under different conditions, Mori’s synthesis of optically 
pure (-)-trans-verbenol from (-)-α-pinene suggests the enantiopurity of Archer’s monoterpene to 
be 87.4% based on the value -135º (c 0.81, CHCl3) for pure (-)-trans-verbenol,75d a purity which 
is supported by the specific rotation of Archer’s (-)-α-pinene (-44.6º (c 1.0, MeOH)). Without 
mention of chiral resolution, it follows that the (-)-20 prepared by Archer using (-)-trans-verbenol 
should have enantiopurity of 87.5%. Since nabilone has no natural source, the only means to 
determine its absolute enantiopurity would be analyze (-)-20 by chiral HPLC with comparison 
against its racemate, however, to the author’s knowledge this has yet to be performed. If indeed 
(-)-20 exhibiting a specific rotation of -55.7º correlates to 87.5% enantiopurity, then the (-)-
nabilone provided following filtration and cyclization as described above corresponds to 98.2% 
enantiopurity. Unfortunately, an authentic sample of (±)-20 is currently unavailable for 
comparison with (-)-20 prepared by the author, as such the definitive determination of 
enantiopurity will be deferred for the time being. Nevertheless, this synthetic route is able to 
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produce (-)-nabilone in greater enantiopurity than previously reported presumably due to the 
filtration process developed to purify 98.
The Michael adduct 98 was originally prepared by the condensation with diacetates 97 
(Scheme 3; Chpt. 1) and the specific rotation of this material has varied only slightly between 
the last two preparations (+57.2° (c 1.0, CHCl3)54c and +55.8° (c 1.0, CHCl3)75a). However, when 
98 is prepared and purified by the filtration described above, the specific rotation dramatically 
increases to +83.6° (c 1.0, CHCl3). This corresponds to a ~32% increase in ee, which is difficult 
to rationalize considering that the diacetates are prepared from (-)-β-pinene (94) which is 
generally purchased at 92.5% optical purity, however, this critical data was not included in 
previous communications.54c,75a During the author’s measurement of the optical rotation of 
filtered 98, the material was observed to be notably less soluble under the conditions described 
by Archer or Drake than samples of Michael adduct that had been purified using column 
chromatography. Suspecting the data to be skewed by the heterogeneity of the sample, the 
optical rotation measurement was repeated with a dilution factor of 10, resulting in a specific 
rotation of +63.7º (c 0.1, CHCl3). Although a direct comparison of these specific rotations is not 
precise, the diluted sample is potentially enantiopure. Unfortunately, without the exact optical 
purity of Archer’s or Drake’s (-)-β-pinene or more specifically their diacetates, the optical purity 
of the final product cannot be determined. The optical purity of the (-)-apoverbenone (99) used 
to prepare 98 has been recorded and may offer insight as to the enantiopurity of the Michael 
adduct. However, this is complicated by the persistent contamination of 99 with (+)-nopinone 
(95) which rotates the plane of polarization of polarized light in the opposite direction and is 
present in variable amounts due to the shortcomings of the method described above. Attempts 
to determine the enantiopurity of 98 without an authentic sample of its racemate was 
challenging but eventually a logical method was developed.
 77
Curiously, samples of 98 purified by column chromatography exhibited a specific rotation 
in agreement with Archer and Drake when diluted to the same concentration (+54.5º (c 1.0, 
CHCl3)). This prompted a further investigation of the filtration process. Michael adduct that had 
been purified by column chromatography was rinsed as previously described and the filtrate, 
which contained small amounts of 98 as judged by TLC, was concentrated and the specific 
rotation of the resulting residue was measured at +35.7º (c, 1.0, CHCl3). The increase in the 
specific rotation of the filtered 98 coupled with the decrease in the specific rotation of the 
Michael adduct in the filtrate suggested that the process designed to quickly purify 98 from the 
Brønsted acid reaction mixture was also removing the racemate of 98 with greater ease than 
the major enantiomer. Additional rinsing of 98 with DCE then presumably dissolves amounts of 
the major enantiomer, giving rise to the nonracemic dextrorotary filtrate. Excited by this result, 
chiral HPLC was performed on the three samples of 98 at the author’s disposal; material that 
was purified by column chromatography, or by filtration, and the filtrate (Experimental p.116). 
According to the data, the Brønsted acid catalyzed Michael addition of 93 to 99 affords a 
95.5:4.5 enantiomeric ratio or 91% enantiomeric excess of 98 following flash chromatography. 
When the scalemic mixture was filtered as previously described and the white crystalline 
Michael adduct was examined under the same conditions the ee improved to >99% — the 
minor enantiomer being undetectable. The postulate that the filtration process successfully 
removed the racemate of 98 more rapidly than the desired antipode was further confirmed when 
the filtrate was analyzed concurrently, resulting in a er of 72:28. It then follows that the (-)-
nabilone prepared from the filtered Michael adduct is enantiopure, as the intramolecular 
cyclobutane ring opening occurs without scrambling of the stereochemistry at C-6a. This solves 
the problem of the cumbersome and unreliable determination of optical purity without the need 
for chiral HPLC comparison of (-)-20 with its racemate. 
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In conclusion, efficient routes to the versatile and optically active ketocannabinoids 105 
and 98 have been developed. During these syntheses, a new facile, catalytic route to 
apoverbenone was developed, which proceeds by the Saegusa-Ito oxidation of nopinone and 
showcases the robust nature of this named reaction. The key step in the synthesis of 105 and 
98 is a Michael addition to apoverbenone which is catalyzed by either Lewis or Brønsted acid 
and precludes the use of lead tetraacetate — a reagent deemed necessary prior to this work 
(Scheme 11, 12, 13, 14). The efficiency of the Michael addition is exemplified during the 
abbreviated total synthesis of (-)-nabilone, which can be performed in four (Scheme 12) or five 
steps (Scheme 14), and was accomplished in 49% or 65% overall yield, respectively. This 
represents a great improvement to the state-of-the-art synthesis of optically active nabilone, 
which led to product in 28% yield over 5 steps. Although the Lewis acid catalyzed Michael 
addition can provide (-)-nabilone in fewer steps, the route that makes use of a Brønsted acid is 
higher yielding. Moreover, this method utilizes p-toluenesulfonic acid and is the preferred route, 
due to the convenience of the filtration process developed to isolate 98, which easily separates 
the racemate of 98 from its major enantiomer in a practical and scalable manner. The  synthesis 
of (-)-nabilone which utilizes the Brønsted acid catalyzed Michael addition is complemented by 
the simple reaction conditions, commercially available reagents, and experimental ease. 
Furthermore, the improved syntheses to 105 or 98 require no exotic or toxic reagents, and, 
importantly, can be applied to the synthesis of classical, non-classical, and hybrid cannabinoids.
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Chapter 3
The Total Synthesis of C-9 and C-11 Functionalized Classical Cannabinoids
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Because of the work outlined in Chapter 2 of this thesis, enantiopure (-)-nabilone was at 
the author’s disposal as the common starting material for the synthesis of targeted 
cannabinoids 83 - 90 (Figure 26). These ligands were prepared to complement the work of Mr. 
Ogawa, and to introduce reactive functionality at C-9 and C-11 so as to probe the cannabinoid 
receptors through LBAs, SARs, and LAPS experiments. These experiments will be performed 
by our collaborators at Northeastern University. Ligands that exhibit high receptor affinity and 
irreversible agonism could potentially be utilized for co-crystallization experiments with CB1 or 
CB2. Successful results from LAPS and co-crystallization would then provide a very highly 
detailed description of the receptor binding pocket, its steric and chemical demands for 
activation, and a framework for logical ligand design. All of this will aid in the ultimate goal of 
modulating the selective activation of the individual regulatory functions controlled by the 
endocannabinoid system.
The same functional groups, nitrate ester, nitrile, azide, and isothiocyanate were chosen 
for both the C-9 and C-11 series. This simplified the retrosynthetic analysis and guided the 
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Figure 26: Targeted C-9 and C-11 Functionalized Ligands
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synthetic plans of both series to an alkyl halide intermediate which could be used for a facile 
displacement by the appropriate nucleophile to furnish the desired functionality. Nitrate esters 
have been prepared by exposure of alcohols to a variety of reagents, however, depending on 
the substrate a number of side reactions or stereochemical scrambling may occur.93 Moreover, 
the reagents necessary for the conversion of alcohols to nitrate esters are often noxious or 
difficult to handle. In contrast, the formation of nitrate esters from alkyl halides by treatment with 
silver nitrate is selective and tolerates a range of substrate functionality — providing nitrate 
esters in good yields with predictable stereochemistry following filtration of the silver halide salt. 
The alkyl halide which could provide a nitrate ester in one step could also furnish nitrile, or azide 
functionality following its treatment with NaCN or NaN3. Although organic azides and nitriles 
may be also be installed by a Mitsunobu reaction of the corresponding alcohol, this is not an 
option for the preparation of a nitrate ester, further increasing the attractiveness of proceeding 
through an alkyl halide — especially for the C-9 series where an axial substitution results in an 
extreme loss of receptor affinity. The resulting azides could then, in a single operation, provide 
the desired isothiocyanate ligands using a Staudinger/aza-Wittig reaction by treatment with 
triphenylphosphine followed by carbon disulfide.94
Examining first the C-11 series, the first goal was to prepare the primary halide (129; 
Scheme 15). This could be made in a number of ways. Based on earlier work from our group,62 
ketone (-)-20 can be homologated and hydrolyzed to provide an aldehyde at C-11, which upon 
reduction would give primary alcohol 134 (Scheme 15). Following the introduction of C-11 via a 
Witting reaction, the hydrolysis which affords the C-11 aldehyde is complicated by an additional 
stereocenter at C-9, and provides a mixture of β-equatorial and α-axial isomers. The β-equatorial 
orientation at C-9 is critical to receptor affinity and can fortunately be controlled by base 
catalyzed epimerization of the diastereomeric C-11 aldehyde mixture. This epimerization 
provides the more stable and potent β-series aldehyde prior to the reduction which furnishes 
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134. Makriyannis and coworkers have recently shown that C-11 hydroxy tricyclic cannabinoids, 
like 134 are well suited for iodination by treatment with triphenylphosphine, imidazole, and 
iodide — providing a straightforward route to halide 129 (X = I; Scheme 15).95 
Following the strategy outlined by the retrosynthetic analysis, a Witting reaction was 
performed on (-)-20 using (methoxymethyl)triphenylphosphonium chloride and n-BuLi (Scheme 
16). The resulting enol ether was hydrolyzed to a mixture of α and β aldehydes (130-mix) using 
wet trichloroacetic acid in DCM, and epimerized with potassium carbonate in absolute ethanol to 
the β-aldehyde (130; Scheme 16). Although the proton-proton coupling constants of H-9 were 
difficult to discern at 500 MHz, extrapolating the J-values from the four α-protons at H-8 and 
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Scheme 15: Retrosynthetic Analysis of C-11 Ligands Using Intermediate 129
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H-10 supported the axial orientation of H-9 — with coupling constants of 3.8, 3.8, 12.5, and 12.5 
Hz.62 The stereochemistry of β-equatorial aldehyde 130 was further confirmed by the positive 
nuclear Overhauser effect (nOe) of H-9 with axial and benzylic H-10a (Scheme 16).
The synthesis of 130 was accomplished in 35% yield over three steps. Although 
serviceable, this rather low yield was unpleasant and the loss of material was determined to be 
occurring during the crucial epimerization step. This was confirmed by the isolation of 130-mix 
which was obtained in 62% overall yield as a 2:1 mixture of β:α aldehydes (a, b; Scheme 16). 
The subsequent epimerization of 130-mix then provided 57% yield of enantioenriched 130. 
Attempts to track the material loss during the epimerization with potassium carbonate afforded 
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Scheme 16: Preparation of β-Aldehyde 130 or 132 from (-)-Nabilonea
aReagents and Conditions: (a) Ph3PCH2OMe+Cl−, nBuLi, THF, −30 °C to 0 °C, 0.5 h; 
(b) CCl3COOH, H2O, CH2Cl2, rt, 1 h; 62% from (-)-20 (2 steps) (c) K2CO3, EtOH, rt, 4 
h; 57% from 130-mix; 85% from 131 (3 steps) (d) TBSCl, Imidazole, 80 ºC, 10 min; 
98%; (e) TBAF, Et2O, rt, 0.5 h; 83%     
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no definitive answers, however, performing the homologation, hydrolysis, and epimerization 
reactions on the phenolic silyl ether 131 provided β-aldehyde 132 in 85% over three steps with 
small amounts of a coeluting impurity (Scheme 16). Aldehyde 132 could be deprotected to 130 
in acceptable yield but was instead used for the subsequent transformations to avoid any 
competitive side reactions of the free phenol en route to halide 129.
Aldehyde 132 was reduced with sodium borohydride in methanol to afford the primary 
alcohol phenolic silyl ether, 133, in 71% yield (a; Scheme 17). The yield could be improved to 
82% by the use of ethanol as the reaction medium (b; Scheme 17). Although the yield of this 
reduction remained relatively low for a reduction of an aldehyde with NaBH4,96 primary alcohol 
133 was isolated without the inseparable impurity that contaminated aldehyde 132, and the loss 
of this adulterant may account for the lower yield.
 
Due to the intended uses of intermediate 129, we initially aspired to install a bromine 
atom at C-11. This bromide would be less reactive than its iodo counterpart, yet would be 
amenable to long term storage, free from the light catalyzed decomposition common to organic 
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Scheme 17: Reduction of C-9 β-Aldehydea
aReagents and Conditions; (a) NaBH4, MeOH, rt, 71%; (b) NaBH4, EtOH, 0 ºC to rt, 82%.
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iodides.97 Although this reaction had been performed by our collaborators on an analogous 
alcohol,95 treatment of 133 with triphenylphosphine and tetrabromomethane only returned 
starting materials. In an attempt to drive the reaction to form the oxophosphonium intermediate, 
NBS was used in place of tetrabromomethane as described by Still and Mitra.98 Under these 
conditions bromination of the electron rich aromatic ring took place before substitution at C-11. 
Similar results were obtained when 133 was added to a premixed solution of Ph3P and Br2 while 
attempting the bromination at C-11.98b The lack of reactivity of 133 toward CBr4, and the 
undesired electrophilic bromination of the aromatic ring by other reagents discouraged any 
consideration of preparing the C-11 chloride. The problem of electrophilic ring chlorination was 
predicted to be more severe with the more highly reactive chlorinating agents. 
Conversion of hydroxyl groups of similar cannabinoids to alkyl iodides has been reported 
a number of times,54c,62,95 without the complicating aromatic substitution that derailed the 
bromination. Thus, heating 133 with triphenylphosphine (Ph3P) in benzene in the presence of 
imidazole and iodine led smoothly to primary monoiodide 135 through a Mitsunobu reaction 
(Scheme 18). Isolation of this halide by column chromatography was accomplished in ca. 85% 
yield, but as 135 was exposed to silica or light, the formation of an exocyclic alkene could be 
detected. This alkene is the result of elimination and was troublesome to separate from 135. 
This led us to use the crude iodide for the subsequent substitution reactions. A major concern 
with using crude 135 was the potential of left over Ph3P from the Mitsunobu reaction which 
could perform a Staudinger reaction on the azide product following displacement. The 
Staudinger reaction could be avoided, however, by carefully controlling the stoichiometry during 
iodination by adding 2.05 equivalents of Ph3P as a standard solution in benzene. Application of 
these modifications followed by nucleophilic displacement with either sodium azide (NaN3), 
sodium cyanide (NaCN), or silver nitrate (AgNO3), and deprotection afforded 88, 86, and 84 in 
76%, 77%, or 82% yield, respectively, over three steps (Scheme 18). 
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Although protecting the phenolic hydroxyl group in ketone 131 greatly improved the yield 
of the C-11 aldehyde, iodination of aliphatic hydroxy cannabinoids has been performed in the 
presence of free phenolic hydroxy functionality without deleterious effect to the yield.95 To 
examine if the phenolic silyl ether was necessary during the Mitsunobu reaction and perhaps to 
avoid carrying a protecting group through a number of steps 133 was deprotected to 134 in 83% 
yield prior to its exposure to Ph3P, imidazole, and I2 (f; Scheme 18). Following iodination and 
nucleophilic displacement by sodium cyanide, 86 was formed in 60% yield over two steps 
(Scheme 18). The low yield was unexpected because the reaction appeared to be clean by 
TLC, suggesting that this process may merit closer scrutiny to determine where the material 
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Scheme 18: Formation of and Substitutions on Advanced Intermediate 135a  
aReagents and Conditions: (a) Ph3P, imidazole, I2, PhH, 80 ºC, 1 h; (b) NaN3, DMF, rt, 
12 h; 76% after f (three steps); (c) NaCN, DMSO, rt, 24 h; 77% from 135 after f (three 
steps); 60% from 134 (2 steps); (d) AgNO3, CH3CN, rt, 12 h; 82% after f (three steps); 
(f) n-Bu4NF, Et2O, rt, 1 h; 83% form 133.
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loss is occurring. Regardless, deprotection of the phenolic silyl ether after the substitution of 135 
leads to 86 in higher yield and with no greater difficulty.
With three of the four targeted C-11 ligands in hand, work to convert 88 to isothiocyanate 
90 was initiated. Although the conversion of azide to isothiocyanate has been described many 
times before, a number of the published reaction conditions when applied to 88 failed to 
produce material that exhibited the broad 2200 and 2100 cm-1 stretching in the infrared 
spectrum characteristic of an -NCS group.103 Initial attempts at the Staundinger/aza-Wittig were 
performed on a model system in which cyclohexylmethyl azide was cleanly converted to 
cyclohexylmethyl isothiocyanate by treatment with triphenylphosphine in chloroform followed by 
carbon disulfide. However, the same conditions applied to 88 produced a complex reaction 
mixture with none of the desired product detected by IR or LCMS. Changing the solvent to 
dioxane, toluene, or benzene, at either room temperature or reflux, and using purified reagents 
provided similarly complex mixtures. 
While it is still unclear why this transformation was so troublesome on the real system, 
the transformation of azide to isothiocyanate was attempted by Mr. Ogawa using carbon 
disulfide and triphenylphosphine during the synthesis of 81 and 82 from their corresponding 
azides with no success (Figure 21).70b The Staudinger reaction has been shown through DFT 
calculations to prefer a cis trajectory with regard to the azide nitrogen bound to carbon (-
CH2N=N=N),99 and this approach may be challenged by the preferred orientation of azide 88. 
Moreover, during the attempts to transform C-11 azide to isothiocyanate, starting material could 
be observed by TLC, suggesting that the initial Staudinger reaction, which provides the 
iminophosphorane (-CH2N=PPh3) required for the aza-Wittig reaction with carbon disulfide, was 
disfavored resulting in side reactions. The failure of the Staudinger/aza-Wittig led to the 
examination of another route to 90 which could be exploited provide C-9 functionalized ligands 
as well.
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Aldehyde 130 could provide, via reductive amination, primary amine 137 that could be 
converted to isothiocyanate 90 in one additional step. A major complication of the reductive 
amination of aldehydes to primary amines is the potential to form symmetric secondary amines. 
To avoid this, numerous methods have been developed, but the most versatile of these is one 
which proceeds through an oxime intermediate (136; Scheme 19). This oxime could not only 
provide access to a C-11 amine (137), but access to two other targets belonging to the C-9 
series as well, nitrile 85 and isothiocyanate 89 (Scheme 19).
The rearrangement of oxime to isothiocyanate has been described by Kim,100 and was 
subsequently validated by Rawal101 during the total synthesis of N-methylwelwitindolinone 
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Scheme 19: Retrosynthetic Analysis using C-11 Oxime
derivatives. This reaction proceeds through the hydroximoyl chloride (VI) of an aldoxime that is 
formed by by exposure to N-chlorosuccinimide, which is treated with triethylamine to provide a 
nitrile oxide (VII; Figure 27). This nitrile oxide then undergoes a [3+2] cycloaddition with 
thiourea in a second step to form an oxathiazoline (VIII) in situ which rapidly rearranges to the 
desired isothiocyanate 89 expelling urea in the process (Figure 27).
This transformation would provide the C-9 isothiocyanate and avoid entirely the 
conversion of azide to isothiocyanate that was found to be challenging in the C-11 series. 
Moreover, the aldoxime to isothiocyanate rearrangement has been shown to proceed with 
retention of stereochemistry at the α carbon atom, further simplifying the synthesis of 89 which 
would retain the β-equatorial orientation of 136. 
Oxime 136 was rapidly formed upon heating 130 with hydroxylamine hydrochloride 
(NH2OH•HCl) and Et3N in dimethylsulfoxide (a; Scheme 20).102 After chromatography, a ~3:1 
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Figure 27: C -9 Isothiocyanate Formation from C-11 Aldoxime via 
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trans:cis mixture of aldoximes was isolated in 82% yield. Following Kim’s procedure, the purified 
oximes were suspended in DMF with one equivalent of N-chlorosuccinimide. Using the 
modifications of Rawal and coworkers, tetrahydropyrimidine-2(1H)-thione and triethylamine 
were added to this solution. These conditions did provide a C-9 isothiocyanate, however, the 
reaction mixture also contained unreacted C-11 aldoxime. Moreover, the electron rich aromatic 
ring of 136 and 89 underwent mono- and dichlorination at C-2 and C-4 rendering a six 
component reaction mixture. The unwanted chlorination was a result of the electrophilic source 
of chlorine and is not surprising, although we had hoped that the formation of the hydroximoyl 
chloride would be faster than aromatic chlorination. 
Examining other methods for the formation of hydroximoyl chlorides from aldoximes 
revealed an interesting reagent, N-tert-butyl-n-chlorocyanamide (NTBNCC).103 This reagent, 
although a powerful electrophilic source of chlorine, had been shown to provide hydroximoyl 
chlorides of substrates incorporating electron-rich aromatic rings or even free phenols without 
chlorination of the ring.103a Thus, 4-hydroxybenzaldoxime was treated with NTBNCC in 
dichloromethane in the presence of tetrahydropyrimidine-2(1H)-thione followed by Et3N. 
Although this model system has functionality that both activates and deactivates the aromatic 
ring, these conditions provided the desired isothiocyanate without chlorination of the aromatic 
system. Unfortunately, when this reaction was repeated with oxime 136, the dually activated 
electron rich aromatic system was chlorinated. Although discouraging, the formation of a 
hydroximoyl chloride need not be the only method to prepare the C-9 isothiocyanate from the 
C-11 oxime. 
The mechanism of the transformation described by Kim depends upon the formation of a 
nitrile oxide, and numerous methods have been developed for this task.104 Searching for a 
procedure that would produce nitrile oxides while employing reagents which do not lead to 
substitution on electron rich aromatic systems suggested a number of iodine reagents.105 The 
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most attractive of these reagents was diacetoxyiodobenzene (DIB), which was described by 
Singhal and coworkers105e and was used to oxidize aromatic oximes to nitrile oxides in situ. 
Although applied to the formation of di- and trisubstitued isoxazoles via [3+2] cycloaddition with 
electron poor olefins, this method should lead to the same unstable intermediate VIII in the 
presence of thiourea, which upon rearrangement would provide isothiocyanate 89. 
Unfortunately, treating the model hydrocinnamaldoxime with DIB in acetonitrile and water in the 
presence of tetrahydropyrimidine-2(1H)-thione did not produce the corresponding 
isothiocyanate, but instead returned the oxime unchanged. Altering the reaction conditions with 
additional sodium acetate to encourage the formation of the crucial nitrile oxide, and/or by using 
CS2 to act as a less electron rich carbon-sulfur olefin were both unsuccessful at forming an 
isothiocyanate from hydrocinnamaldoxime. The failure to generate a nitrile oxide from the model 
system was discouraging given the simplification this reaction would grant to the synthesis of 
89.
Turning attention to the other C-9 functionalized ligand which is derived from the C-11 
aldoxime, 130 was treated with NH2OH•HCl in DMSO and heated for one hour.102 This allowed 
for a simple one step formation of C-9 nitrile in 86% yield after chromatography (b; Scheme 20). 
Although the stepwise formation of 85 was also possible by the subsequent treatment of purified 
136 with hydrochloric acid in DMSO, this two step process led to a lower yield than the one step 
procedure and also required more effort, so this approach was abandoned. 
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Primary amine 137 could be obtained by the reduction of either 136 or nitrile 85 using 
lithium aluminum hydride, but these routes were poor yielding, mostly due to difficulties 
encountered during the isolation of the product from the reaction mixture. The most convenient 
and simple stepwise reductive amination which provided primary amine 137 was performed by 
treating aldehyde 130 with hydroxylamine hydrochloride in ethanol, followed by the addition of 
zinc dust and concentrated HCl (c; Scheme 20).106a This reaction was further simplified by a 
clever work-up which eased the isolation of the 137. Primary amines have been shown to form 
complexes with Zn2+ which is produced during the course of this reduction,106b however, 
treatment of the resulting crude reaction mixture with ammonia in the presence of sodium 
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aReagents and Conditions: (a) NH2OH•HCl, Et3N, DMSO, 90 ºC, 1 h; 82%; (b) 
NH2OH•HCl, DMSO, 90 ºC, 1 h; 86%; (c) NH2OH•HCl, EtOH, rt, 6 h, then Znº, HCl 
(conc.) (d) CS2, Et3N, THF, 0 ºC, 2 h, then p-TsCl, 0 ºC to rt, 2 h; 61% from 130
Scheme 20: Functional Group Conversions of C-11 Aldehydea
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hydroxide can dissociate this complex, allowing the desired primary amine to be isolated by a 
simple extraction with DCM. This crude amine was then used to provide the final C-11 ligand, 
isothiocyanate 90. Treating the primary amine with triethylamine and carbon disulfide followed 
by p-toluenesulfonyl chloride (p-TsCl) as described by Ho107 provided a 3:1 mixture of 
isothiocyanates; the desired 90, and phenolic tosylate 138 (Scheme 20). The formation of 138 
could be suppressed by using equimolar amounts of p-TsCl and 137. Using optimized 
conditions 90 was produced in 61% overall yield from aldehyde 130 (d; Scheme 20).
This concluded the total synthesis of the four C-11 targets, all of which could be obtained 
in seven synthetic steps in overall yields between 41-54% from optically active nabilone. This 
route also conveniently provided C-9 nitrile 85 after 6 steps in 58% overall yield from (-)-
nabilone.
The remaining three targets consisted of C-9 nitrate ester, azide, and isothiocyanate. 
The relative ease by which the C-11 nitrate ester and azide were produced via iodide 135 led 
the author to a similar synthetic plan for the C-9 targets, using axial iodide 140 (Scheme 21). 
Given the challenge presented by the direct conversion of C-11 azide to the corresponding 
isothiocyanate, a stereospecific reductive amination of 20 to produce 141 was considered for 
the expeditious synthesis of 89 (Scheme 22). Whether this reductive amination would proceed 
through an oxime intermediate, as with the C-11 series, was unclear at the time and both 
methods were eventually explored.
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Starting with the more straightforward synthesis of the secondary iodide 140, phenolic 
silyl ether 131 was reduced with sodium borohydride to afford secondary equatorial alcohol 139 
in 85% yield (a; Scheme 22). Treatment of 139 under the Mitsunobu conditions previously 
described for the preparation of the C-11 primary iodide led to a large amount of ∆8 and ∆9 
elimination products. This was unfortunate but not surprising given the elevated temperature 
used for this transformation, and that the axial iodide is locked into the ideal configuration for 
elimination with two  different antiperiplanar α-hydrogens. The unwanted elimination could be 
ameliorated by reducing the temperature at which this reaction was performed. Similar to the 
C-11 series, crude iodide 140 was used directly for the substitution with either sodium azide or 
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Scheme 21: Retrosynthetic Plan for Remaining C-9 Targets
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silver nitrate providing 87 or 83 after deprotection in 65% or 72% yield over three steps, 
respectively (b, c or d, then e; Scheme 22).
The reductive amination needed to furnish primary amine 141 posed a greater challenge 
than that of the C-11 amine because stereochemistry at C-9 had to be controlled. While there is 
a large volume of research dedicated to reductive aminations of cyclic ketones,108 we desired a 
simple method that could control stereochemistry without the need for expensive or exotic 
ligands or catalyst. Moreover, to provide the desired β-equatorial primary amine at C-9, a small 
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aReagents and Conditions: (a) NaBH4, EtOH, 0 ºC to rt, 85%; (b) Ph3P, 
imidazole, I2, PhH, 50 ºC, 1 h; (c) NaN3, DMF, rt, 12 h; 65% after e (three steps); 
(d) AgNO3, CH3CN, rt, 12 h; 72% after e (three steps) (e) n-Bu4NF, Et2O, rt, 1 h
Scheme 22: Formation of and Substitutions on Advanced Intermediate 140a
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reducing agent would need to be employed to favor axial approach to the rigid tricyclic scaffold. 
With this in mind, the stepwise reductive amination of the C-9 ketoxime was initially attempted. 
Although the method employed for the preparation of C-11 amine was not described for 
ketoximes, its experimental ease and success urged its employment for the stepwise reductive 
amination of (-)-20. (-)-Nabilone was treated with hydroxylamine hydrochloride in ethanol 
followed by zinc dust and hydrochloric acid. Unfortunately, this provided only a mixture of cis 
and trans oximes which were not reduced by the treatment with Zn0 and HCl. Turning our 
attention to other stepwise methods of reductive amination which could provide 141, the 
ketoxime derivatives of (-)-nabilone were heated in methanol with ammonium formate and Zn0 
following the work described by Abiraj or Johnson.109 Unfortunately neither of these methods 
was successful in producing the primary amine 141, and left the mixture of ketoximes 
unchanged.
Contemporaneously with the ketoxime reductions discussed above, one-step reductive 
aminations of (-)-20 were attempted. The comprehensive review of the reductive amination of 
carbonyls using sodium triacetoxyborohydride which has been written by Abdel-Magid and 
coworkers described the stereoselective synthesis of primary amines from ketones.108a When 
these methods were applied in combination with experimental efforts described by Cabral and 
coworkers110 an attractive procedure for the production of 141 was developed. Thus, (-)-
nabilone was dissolved in methanol in the presence of sodium cyanoborohydride (NaBH3CN) 
and ammonium acetate (NH4OAc, a; Scheme 23).  Within a day this produced a crude primary 
amine that was subjected to standard isothiocyanation conditions (b; Scheme 23). After 
purification of the final product, this two step process provided isothiocyanates 89 in 37% yield 
as a 3.2:1 β:α ratio. Due to the success, simple reagents, and experimental ease of this 
reductive amination method, the reductions of ketoximes were not examined any further. The 
synthesis of 89 was improved by conducting the reductive amination at a lower temperature. 
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Additionally, acetic acid was added to the reaction mixture to encourage imine formation. 
Keeping the temperature of the reduction at 4 ºC for 48 hours provided a 4.3:1 dr after 
isothiocyanation to 89 while increasing the yield to 71% over two steps (b; Scheme 23). Noting 
the increased diastereoselectivity at lower temperature encouraged further investigation, and 
the reductive amination of (-)-20 was repeated at -15 ºC. The decreased temperature did further 
improve the dr to 5.1:1 of β:α amines as judged by the integration of the resulting C-9 methine 
proton by 1H NMR. However, the amination did not proceed to completion at this temperature 
after 5 days, and following the isothiocyanation of 141, the mixture of 89-ax and 89 was isolated 
in 49% yield. This decrease in yield is presumably caused by the low solubility of NaBH3CN in 
methanol at low temperature, an issue which has been previously noted with NaBH4 and shown 
to cause similar deleterious effects on reductive aminations.110 While the lack of stereospecificity 
is an issue for the synthesis of 89, or more specifically 141, this method is simple to perform, 
requires no exotic reagents, and the only byproduct is 89-ax, which can be separated from the 
desired 89 by chromatography.
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Scheme 23: Reductive Amination of Nabilonea
aReagents and Conditions: (a) NaCNBH3, MeOH, NH4OAc, 4 ºC, 24 h; (b) CS2, 
Et3N, THF, 0 ºC, 2 h, then p-TsCl, 0 ºC to rt, 2 h; 71% from (-)-20
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This concludes the total synthesis of the functionalized C-9 and C-11 classical 
cannabinoid series. Ligands 83 - 90 have been transferred to our collaborators at Northeastern 
University, who are charged with the completion of ligand binding assays, structure activity 
relationships, and ligand assisted protein structure experiments.
In Chapter 2, the synthesis of enantioenriched ketocannabinoids was described. The 
improvements to the synthetic route to ketocannabinoids have been exemplified by the 
abbreviated total synthesis of enantiopure nabilone — whose racemate is the only synthetic 
cannabinoid to currently hold FDA approval. The state of the art total synthesis of (-)-nabilone 
prior to the work of Chapter 2 was accomplished in 5 steps to afford 28% overall yield. 
Revisions herein allow (-)-nabilone to be prepared in 5 steps, but increase the overall yield to 
65% by utilizing a Brønsted acid catalyzed Michael addition to apoverbenone which had been 
overlooked for decades. The high yield is complemented by a filtration process developed for 
the Michael adduct, which is provided in exceptional ee as is the resulting (-)-nabilone following 
cyclization. Additionally, the abbreviated synthesis exhibits greater experimental ease than the 
previously described routes and avoids the use of highly toxic lead tetraacetate which has 
served as a constant reminder of the era in which the total syntheses of (-)-nabilone and 
ketocannabinoids were initially reported.
Chapter 3 utilized the work of the previous chapter by describing the derivitization of 
nabilone to eight target ligands — the syntheses of which is described. These eight ligands 
were prepared to examine the pharmacological properties of the azide, cyano, isothiocyanate, 
and nitrate ester functionality at C-9 and C-11 of the classical cannabinoid scaffold. The 
challenges that have been encountered during the preparation of these ligands have been 
largely overcome with the exception of the reductive amination of (-)-nabilone which is not highly 
stereoselective but is simple to perform and adequate for the preparation of C-9 β-
isothiocyanate 89.
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With a more efficient route to highly enantiopure (-)-nabilone and related synthetic 
cannabinoids at the disposal of chemists, many more unique ligands can be prepared and 
examined for their pharmacological properties. The availability of functionalized bi- and tricyclic 
cannabinoids will enable the mapping of the CB1 and CB2 receptors. A better knowledge of the 
receptor binding site may make it possible to design cannabinoids with modulated selectivity 
and affinity for CB1, CB2, or both cannabinoid receptors to potentially aid in the selective 
manipulation of the endocannabinoid system. Attached is a description of the key experiments 
performed.
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Experimental  
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General
1H NMR and 13C NMR spectra were recorded at 500 MHz (1H) and 126 MHz (13C). 
Chemical shifts are reported in parts per million (δ) and are referenced to the solvent, 
i.e. 7.26/77.0 for CDCl3. Multiplicities are indicated as; app (apparant), br (broadened), s 
(singlet), d (doublet), t (triplet), q (quartet), p (pentet), or m (multiplet). Coupling 
constants (J) are reported in Hertz (Hz). Thin layer chromatography (TLC) was 
performed on glass plates 250 μm, particle size 5-17 μm, pore size 60 Å. Flash column 
chromatography was performed on silica gel, 200-400 mesh, or premium silica gel, 60 
Å, 40-75 μm. All moisture sensitive reactions were performed under a static atmosphere 
of nitrogen or argon in oven-dried or flame-dried glassware. Purity and homogeneity of 
all materials was determined to be at least 95% from TLC, 1H NMR, 13C NMR, and LC–
MS. Target ligands prepared for biological examination were purified to 99% as 
evaluated at 254 nm as well as 230 nm by normal phase HPLC using a Shimadzu 
system consisting of LC-20AT solvent delivery modules, an SPD-20A VP diode 
photodiode array detector, and an SCL-20A VP system controller. High-resolution mass 
spectrometric data were obtained on an Agilent LC-MSTOF with ESI ionization in the 
positive or negative mode. All infrared spectroscopy were measured using a Shimadzu 
IRAffinity-1 FT-IR using NaCl plates. All optical rotations were measured on a Jasco-
DIP-370 polarimeter at the sodium line (589 nm) in a 0.1 dL cell and concentration, c, is 
expressed in g/100mL. Melting points were measured using a DigiMelt MPA 160.
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Synthesis of 99 — (Scheme 8; Chpt. 2). Under N2, diisopropylamine (2.33 g, 23.03 mmol, 1 
eq) was dissolved in THF (23 mL, 1 M) and cooled to -78º C. A solution of n-BuLi (10 mL of 1.4 
M solution in hexanes, 21.87 mmol, 0.95 eq) was added dropwise to the diisopropylamine 
solution and the resulting mixture was stirred for 10 minutes at -78 ºC. The resulting LDA 
solution was warmed to 0 ºC and let stir for 10 minutes before cooling again to -78  ºC.  
In a separate flame dried flask under N2, 95 (2 g, 14.47 mmol) was dissolved in THF (4 
mL) and slowly added to the LDA solution. The reaction was allowed to stir at -78 ºC for one 
hour to ensure adequate enolate formation. TMSCl* (2.52 g, 23.15 mmol, 1.6 eq) was then 
added to the solution and stirring was continued at -78 ºC for 10 minutes. At this time, the 
reaction mixture was warmed to 0 ºC and stirred for an additional 10 minutes before the addition 
of aqueous NH4Cl. The aqueous phase was extracted with EtOAc (3x), and the combined 
organic layers were washed with water and brine before drying over MgSO4 and concentrating 
under reduced pressure. The crude silyl enol ether was azeotroped in benzene to afford 
intermediate 125 (3.03 g, 99% yield).
A flame dried, 2-neck flask equipped with a 3-way gas inlet and O2 balloon was charged 
with Pd(OAc)2 (0.161 g, 0.72 mmol, 0.05 eq). Anhydrous DMSO (150 mL, 0.096 M) was added 
to the flask and the resulting suspension was vigorously stirred. Crude 125 (3.03 g, 14.46 mmol) 
was added to the resulting suspension and the reaction mixture was purged with oxygen twice 
before stirring at room temperature for 36 h under an O2 atmosphere. After 36 hours water was 
added to the reaction mixture and the aqueous layer was extracted with Et2O (3x). The organic 
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layers were combined and washed with water and brine before drying over MgSO4 and 
concentrating under reduced pressure. The resulting oil was purified via flash chromatography 
(5:95 EtOAc:Hexanes as eluent) to afford 99** (1.67g, 85% yield) as a clear oil. Alternatively 99 
may be distilled under reduced pressure following the method described by Grimshaw in J. 
Chem. Soc. Perkin Trans. I, 1972, 50–52. Spectral data matched previous report by Grimshaw. 
Rf = 0.60 (1:4 EtOAc:n-hexanes); [α]20D +311.0° (c 2.4, CHCl3) [lit.84a [α]25D +319° (c 2.4% in 
CHCl3)]; 1H NMR (500 MHz, CDCl3) δ 7.50 (dd, J = 8.7, 7.0, Hz, 1H), 5.92 (dddd, J = 8.9, 1.7, 
1.0, 1.0 Hz, 1H), 2.82 (dddd, J = 9.7, 5.5, 5.5, 1.0 Hz, 1H), 2.68 (ddd, J = 6.1, 6.1, 1.9 Hz, 1H), 
2.57 (app q, J = 5.8 Hz, 1H), 2.11 (app d, J = 9.2 Hz, 1H), 1.48 (s, 3H), 1.00 (s, 3H); 13C NMR 
(125 MHz, CDCl3) δ 204.2, 157.1, 125.7, 58.7, 55.1, 43.9, 42.0, 26.6, 22.3; IR (neat); 2980, 
2955, 2872, 1683, 1468, 1387, 1369, 1302, 1279, 1245, 1233, 1202, 1130, 1064, 1043, 978, 
859, 840, 789, 764, 731, 668 cm-1; HRMS (ESI) m/z: 137.0961 [M+H]+. Exact mass calculated 
for C9H12O 136.0888; found 136.0882.
*Note: TMSCl was either distilled prior to use or pre-mixed with Et3N and centrifuged 
prior to use avoid introducing residual HCl. 
**Note: Using 5% Pd(OAc)2 to catalyze the Saegusa-Ito oxidation of 125 provides a 96:4 
mixture of 99 and 95 as determined by 1H NMR. See Appendix I, pages 179-181. 
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In general: Silylation was performed according to the procedure outlined by M. A. Tius et al. in J. 
Med. Chem., 2010, 53, 5656-5666. Due to the instability of 101, it is freshly prepared before 
use.
Synthesis of 101 — (c; Scheme 10; Chpt. 2). A flask equipped with a strong stir bar and under 
a N2 atmosphere was charged with phloroglucinol, 100 (5.50 g, 43.7 mmol) suspended in 
CH2Cl2 (300 mL, 0.15 M) and cooled to 0º C. Triethylamine (24.3 mL, 174.6 mmol, 4 eq) was 
added to the suspension followed by slow addition of TMSCl (22.3 mL, 174.6 mmol, 4 eq). The 
reaction mixture was allowed to warm to room temperature and was monitored by TLC. [eluting 
with EtOAc:Hexanes 1:4, 100 Rf = 0.01, 101 Rf = 0.92]. When the reaction was complete (~3 h) 
the reaction was quenched with saturated aqueous NH4Cl. The organic layer was separated, 
washed with brine and water, and dried briefly over Na2SO4 and concentrated under reduced 
pressure. The resulting residue was azeotroped with benzene to provide crude 101 (12.57 g, 
84% yield), as a ruby colored oil which was used without further purification.
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Synthesis of 104 — (d, e; Scheme 10; Chpt. 2). A dry 2-neck round bottom flask 
equipped with a stir bar, septum and 3-way gas inlet was purged with nitrogen. Under a stream 
of nitrogen vanadyl triflate* (36 mg, 0.1 mmol, 0.1 eq) and freshly generated 101 (685.3 mg, 2.0 
mmol, 2.0 eq) were added to the reaction vessel. The mixture of catalyst and 101 was allowed 
to stir under inert atmosphere briefly before the addition of CH2Cl2 (9 mL) to the flask. In a 
separate dry flask 99 (136.2 mg, 1.0 mmol) was dissolved in CH2Cl2 (1 mL) and added to the 2-
neck flask via cannula. The reaction mixture was stirred at ambient temperature until judged to 
be complete by TLC (~48 h), at which point the reaction mixture was transferred to a separatory 
funnel using EtOAc. Warm water (~50 ºC) was added to the reaction mixture and the organic 
layer was separated. The aqueous phase was extracted with EtOAc, and the combined organic 
layers were dried over Na2SO4, and concentrated in vacuo. 
To the resulting residue was added DMAP (6.1 mg, 0.05 mmol, 0.05 eq) followed 
sequentially by DCM (10 mL), pyridine (0.644 mL, 8.0 mmol, 8 eq), and acetic anhydride (754 
mL, 8.0 mmol, 8 eq). This mixture was allowed to stir for 12 hours at room temperature before 
cold water was added to the reaction mixture. The organic layer was washed with 1M HCl, 
brine, dried over MgSO4, and concentrated under reduced pressure. Purification by flash 
chromatography (1:4 EtOAc:n-hexanes eluent) provided 104 (166 mg, 63% yield over two 
steps) as a white solid. Spectral data matched previous reports by Dixon in J. Med. Chem. 
2010, 53, 5656–5666.
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*Note: Vanadyl triflate was prepared as described by Chien-Tien Chen et al. in 
Org. Lett. 2007, 9, 5195-5198, as follows:
To a 50-mL, two-necked, round-bottomed flask was added vanadyl sulfate, vanadyl 
sulfate (342 mg, 2.1 mmol) followed by addition of MeOH (2 mL). To the methanolic 
solution of vanadyl sulfate was slowly added a solution of Ba(OTf)2 (872 mg, 2.0 mmol) 
in MeOH (2 mL) at ambient temperature. After stirring for 30 min, the reaction mixture 
was filtered through a short pad of dry Celite® to remove the precipitate, barium sulfate. 
The filtrate was concentrated to give faint blue solid which was further dried at 120 ºC for 
4 hours under vacuum to furnish vanadyl triflate (622 mg, 85% yield) as a blue powder, 
which was stored in a dessicator.
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Synthesis of 102 — (b; Scheme 13; Chpt. 2). A dry 2-neck round bottom flask equipped with a 
stir bar, septum and an addition funnel with a metering stopcock and 3-way gas inlet was 
purged with nitrogen. Under a stream of nitrogen 100 (116.0 mg, 0.92 mmol, 2 eq) followed by 
p-TsOH (114.0 mg, 0.60 mmol, 1.3 eq) were added to the reaction vessel and dissolved in 
acetone (1 mL). The mixture of acid and 100 were allowed to stir for until homogeneous (~3 
min). In a separate dry flask 99 (63.0 mg, 0.46 mmol) was dissolved in DCE (4 mL) and added 
to the addition funnel via cannula. The entire system was purged with nitrogen for 5 min before 
the stopcock was opened at a flow rate of 1 drop/20 sec. Note: A flow rate faster than this will 
result in the formation of large amounts of bis-addition denoted by heterogeneity of the reaction 
mixture. When the addition of 99 to 100 was complete the reaction was quenched with 
phosphate buffer and extracted with EtOAc (3x). Depending on the size of reaction, either of two 
extraction methods can be employed. A description of both follows;
1. The organic layers were combined and washed with warm water (~70 ºC; 5x)* before 
being dried over MgSO4 and concentrated in vacuo to afford 102 (84.2 mg, 69% yield) as a 
white foam which was used without purification. Spectral data matched previous reports by 
Dixon in J. Med. Chem.  2010, 53, 5656–5666. 
2. Using an Aldrich® modified convertible liquid-liquid continuous extractor (Figure 28): A 
round bottom flask (C) equipped with a boiling chip, continuous extractor, and reflux condenser 
(B) is filled halfway with water and purged with nitrogen (Figure 28). The extractor (G) is also 
 108
HO
OH
O
OH
O
99
HO
OH
OH
100
+
102
filled hallway with water, and the stopcock (D) is opened to 
allow the water in G to flow through E to the round bottom 
flask. Under a stream of nitrogen the combined organic 
layers are carefully added to G. Heat is applied to the round 
bottom flask to achieve rapid reflux, which is continued until 
100 is completely removed from the organic portion of G as 
judged by TLC (~24 h). The contents of G are transferred to 
a separator funnel where the aqueous layer is removed and 
the organic layer is washed with brine then dried over 
MgSO4 and concentrated in vacuo to afford 102 (79.4 mg, 
65% yield) as a white foam. Spectral data matched 
previous reports by Dixon in J. Med. Chem.  2010, 53, 
5656–5666.
*Note: Care should be taken when handling warm water. Also, EtOAc boils at 77.1º C — 
as such the warm water wash should be performed quickly in a separatory funnel to avoid the 
build up of excess pressure. 
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Figure 28: Continuous 
Extraction Apparatus, Courtesy 
of Sigma-Aldrich®, ref.92b
Synthesis of 104 — (c; Scheme 13; Chpt. 2) To the foam 102 (96.4 mg, 0.36 mmol) was 
added DMAP (2.0 mg, 0.02 mmol, 0.05 eq) followed sequentially by DCM (5 mL), pyridine (0.12 
mL, 1.47 mmol, 4 eq), and acetic anhydride (0.140 mL, 1.47 mmol, 4 eq). This mixture was 
allowed to stir for 12 hours at room temperature before cold water was added to the reaction 
mixture. The organic layer was washed with 1M HCl, brine, dried over MgSO4, and concentrated 
under reduced pressure. Purification by flash chromatography (1:4 EtOAc:n-hexanes eluent) 
provided 104 (117.5 mg, 82% yield) as a white solid. Spectral data matched previous reports by 
Dixon in J. Med. Chem.  2010, 53, 5656–5666.
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Synthesis of 105 — (d; Scheme 13; Chpt. 2) The foam of 102 (85.0 mg, 0.32 mmol) was 
dissolved in CH3NO2 (5 mL) and cooled to 0º C under a nitrogen atmosphere before the 
dropwise addition of TMSOTf (0.17 mL, 0.97 mmol, 3.0 eq). The reaction was stirred at 0º C for 
2.5 hours before quenching with solid K2CO3. The suspension was stirred for an additional 45 
min before the solids were filtered off and the solution was concentrated under reduced 
pressure. The residue was purified by flash chromatography (50% EtOAc in hexanes eluent) to 
afford 105 (66.4 mg, 78% yield) as a white foam that typically contains 10-15% EtOAc. Spectral 
data matched previous reports by Dixon in J. Med. Chem.  2010, 53, 5656–5666..
 111
HO
OH
O
OH O
OH
O
OH
105102
Synthesis of 98 — (d; Scheme 13; Chpt. 2). A dry 2-neck round bottom flask equipped with a 
stir bar, septum and 3-way gas inlet was purged with nitrogen and charged with vanadyl triflate 
(36.5 mg, 0.1 mmol, 0.1 eq). White crystalline 93 (236.0 mg, 1.0 mmol) was transferred to the 
reaction vessel under a stream of nitrogen. The mixture of catalyst and 93 was suspended in 
dichloroethane (9 mL). In a separate dry flask 99 (143.0 mg, 1.05 mmol, 1.05 eq) was dissolved 
in dichloroethane (1 mL) and added to the 2-neck flask via cannula. The resulting deep green 
suspension was heated to 60 ºC at which point it became a homogeneous solution. Stirring 
continued at 60 ºC until 93 was completely consumed as determined by TLC (48 h). [99 Rf = 
0.60, 98 Rf = 0.26, 93 Rf = 0.14 (1:4 EtOAc:n-hexanes)] The reaction mixture was concentrated 
and purified by flash chromatography (1:4 EtOAc:n-hexanes eluent) to afford 98 as an off white 
solid (273 mg, 83% yield). Physical and spectral data were identical to those reported earlier in 
ACS Med. Chem. Lett. 2014, 5, 400−404. 98; Rf = 0.26 (1:4 EtOAc:n-hexanes eluent); mp 169.9
—173.5 ºC [lit.75 mp 171—174ºC]; [α]20D +55.2° (c 1.0, CHCl3) [lit.75 [α]20D +55.8° (c 1.0, CHCl3)]; 
1H NMR (500 MHz, CDCl3) δ 6.28 (s, 2H), 5.14 (s, 2H), 3.94 (app t, J = 8.2 Hz, 1H), 3.51 (dd, J 
= 18.8, 7.8 Hz, 1H), 2.67-2.57 (m, 2H), 2.55-2.44 (m, 2H), 2.31 (app t, J = 5.5 Hz, 1H), 
1.52-1.45 (m, 2H), 1.36 (s, 3H), 1.28-1.14 (m, 6H), 1.19 (s, 6H), 1.05 (m, 2H), 0.99 (s, 3H), 0.85 
(t, J = 6.7 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 216.9, 154.7 (2 C), 150.0, 113.5, 106.6 (2 C), 
57.9, 46.8, 44.4, 42.2, 37.9, 37.2, 31.8, 30.0, 29.5, 28.7, 26.2, 24.6, 24.4, 22.7, 22.2, 14.1; IR 
(neat) 3300, 2920, 1680, 1580, 1420, 1370, 1330, 1265 cm-1; HRMS ESI m/z: 373.2743 [M+H]+. 
Exact mass calculated for C24H36O3, 372.2655; found, 372.2648.
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Synthesis of (-)-20 — (f; Scheme 13; Chpt. 2) A dry 2-neck round bottom flask equipped with a 
stir bar, septum and 3-way gas inlet was purged with nitrogen and charged with vanadyl triflate 
(1.5 mg, 0.004 mmol, 0.01 eq). White crystalline 93 (122.8 mg, 0.52 mmol) was transferred to 
the reaction vessel under a stream of nitrogen. The mixture of catalyst and 93 was suspended 
in dichloroethane (9 mL). In a separate dry flask 99 (77.8 mg, 1.1 mmol, 1.1 eq) was dissolved 
in dichloroethane (1 mL) and added to the 2-neck flask via cannula. The resulting deep green 
suspension was heated to 60 ºC at which point it became a homogeneous solution. Stirring 
continued at 60 ºC until 93 was completely consumed as determined by TLC (48 h). The 
reaction mixture was then cooled to 0 ºC, and trimethylsilyl trifluoromethanesulfonate (1.13 mL 
of a 0.3M solution in CH3NO2, 0.34 mmol, 0.34 eq) was added dropwise. The reaction mixture 
was allowed to warm to room temperature and stirring continued at room temperature until the 
reaction was complete as monitored by TLC (3 h). The reaction mixture was quenched by the 
addition of saturated aqueous NaHCO3:brine (1:1), and extracted with Et2O. The combined 
organic phases were washed with water and brine, dried over MgSO4, and concentrated in 
vacuo. Flash chromatography on silica gel (15% acetone in n-hexanes eluent) provided (-)-20 
(116.5 mg, 60% yield over 2 steps) as a white foam. Physical and spectral data were identical to 
those reported earlier in ACS Med. Chem. Lett. 2014, 5, 400−404. (-)-20 Rf = 0.16 (15% 
acetone in n-hexanes). [α]20D -54.8° (c 1.0, CHCl3) [lit.75 [α]20D -55.7° (c 1.0, CHCl3)]; 1H NMR 
(500 MHz, CDCl3) δ 6.81 (br s, 1H), 6.37 (d, J = 2.0 Hz, 1H), 6.33 (d, J = 2.0 Hz, 1H), 4.09 (ddd, 
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J = 15.0, 3.5, 2.5 Hz, 1H), 2.89 (ddd, J = 15.0, 11.5, 3.5 Hz, 1H), 2.63 (dddd, J = 15.0, 4.0, 3.5, 
2.0 Hz, 1H), 2.47 (ddd, J = 15.0, 13.5, 7.0 Hz, 1H), 2.21-2.11 (m, 2H), 1.97 (ddd, J = 12.0, 11.5, 
2.5 Hz, 1H), 1.56-1.46 (m, 3H), 1.48 (s, 3H) 1.28-1.15 (m, 6H), 1.21 (s, 6H) 1.13 (s, 3H), 
1.10-1.02 (m, 2H), 0.84 (t, J = 7.0 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 213.7, 154.7, 154.2, 
150.8, 107.7, 107.2, 105.5, 76.6, 47.3, 45.0, 44.3, 40.8, 37.3, 31.7, 29.9, 28.7, 28.6, 27.8, 26.8, 
24.5, 22.6, 18.8, 14.0; IR (neat) 3300, 2920, 1680, 1580, 1420, 1370, 1330, 1265 cm-1; HRMS 
ESI m/z: 373.2743 [M+H]+. Exact mass calculated for C24H36O3, 372.2655; found, 372.2648.
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Synthesis of 98 — (d; Scheme 15; Chpt. 2). To a dry 2-neck round bottom flask equipped with 
a 3-way gas inlet, stir bar, and septum was added p-toluenesulfonic acid (95.7 mg, 0.5 mmol, 
0.1 eq) followed by white crystalline 93 (1.19 g, 5.03 mmol). The reaction vessel was then 
purged with N2. In a separate dry flask 99 (760.2 mg, 5.58 mmol, 1.11 eq) was dissolved in 
dichloroethane (10 mL, 0.5M with respect to 93) under N2 and transferred to the 2-neck flask via 
cannula. The resulting reaction mixture was warmed to 60 ºC at which point the reaction 
solution became homogenous. Stirring was continued at 60 ºC for 24 h. The resulting 
heterogenous reaction mixture was concentrated under reduced pressure to provide a light 
brown amorphous solid. The solid was washed with cold DCE (3 x 1mL) to provide 98 (1.75 g, 
94% yield - as determined from 93) as a white solid. Purity of the solid was 99% as determined 
by LCMS and ELSD. Physical and spectral data with the exception of specific rotation and 
melting point were identical to those reported earlier in ACS Med. Chem. Lett. 2014, 5, 
400−404. 98; Rf = 0.26 (1:4 EtOAc:n-hexanes eluent); mp 174.2—175.3 ºC, [lit.75 mp 171—174 
ºC]; [α]20D +83.6° (c 1.0, CHCl3) and [α]20D +63.8° (c 0.1, CHCl3), [lit.75 [α]20D +55.8° (c 1.0, 
CHCl3)]; 1H NMR (500 MHz, CDCl3) δ 6.28 (s, 2H), 5.14 (s, 2H), 3.94 (app t, J = 8.2 Hz, 1H), 
3.51 (dd, J = 18.8, 7.8 Hz, 1H), 2.67-2.57 (m, 2H), 2.55-2.44 (m, 2H), 2.31 (app t, J = 5.5 Hz, 
1H), 1.52-1.45 (m, 2H), 1.36 (s, 3H), 1.28-1.14 (m, 6H), 1.19 (s, 6H), 1.05 (m, 2H), 0.99 (s, 3H), 
0.85 (t, J = 6.7 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 216.9, 154.7 (2 C), 150.0, 113.5, 106.6 (2 
C), 57.9, 46.8, 44.4, 42.2, 37.9, 37.2, 31.8, 30.0, 29.5, 28.7, 26.2, 24.6, 24.4, 22.7, 22.2, 14.1; 
IR (neat) 3300, 2920, 1680, 1580, 1420, 1370, 1330, 1265 cm-1; HRMS ESI m/z: 373.2743 [M
+H]+. Exact mass calculated for C24H36O3, 372.2655; found, 372.2648.
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Resolution of 98. Following flash chromatography, small amounts of 98 were resolved using a 
Shimadzu system consisting of LC-20AT solvent delivery modules, an SPD-20A VP diode 
photodiode array detector, and an SCL-20A VP system controller equipped with a Chiralpak OD 
column using 7% isopropanol in hexanes as the mobile phase at a flow rate of 2 mL/min. 
Additionally, 98 was filtered as described above and the freshly filtered crystals as well as the 
filtrate were resolved under the same conditions. Fractions were detected by UV (λ = 254 nm). 
Retention times for (+)-98 and (-)-98, under these conditions were 4.2 min and 8.8 min, 
respectively, and the enantiomeric ratio, and consequently the enantiomeric excess, of 98 was 
determined by the integration of these peaks and are as followed: Column: 95.5:4.5; Filtrate: 
71.8:28.2. No minor isomer was detected in 98 purified by filtration. The existence of (-)-98 was 
confirmed by HRMS and 1H NMR and the spectral data was identical to that obtained for 98.
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Figure 29: Overlayed Chromatograms Obtained from Chiral HPLC.
98 Purified by Flash Chromatography (Green), 98 Purified by Filtration (Black), Filtrate 
Obtained after Filtration of 98 (Red)
Filtration
Column
Filtrate
Column
Filtration
Filtrate 
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Figure 30: Overlayed Chromatograms 
Obtained from Chiral HPLC.
98 Purified by Chromatography, 
98 Purified by Filtration, 
Filtrate Obtained after Filtration of 98
Filtration
Column
Filtrate 
Filtration
Column
Filtrate 
In general: Cyclobutane ring opening was performed according to the general procedure 
outlined by S. P. Nikas et al. in Tetrahedron 2007, 63, 8112–8123.
Synthesis of (-)-20 — (e; Scheme 15; Chpt. 2) A dry round bottom flask under nitrogen 
equipped with a stir bar and septum was charged with 98 (373.3 mg, 1.0 mmol). To the flask 
was added a 3:1 mixture of CH2Cl2:CH3NO2 (7 mL) and the resulting suspension was cooled to 
0 ºC before the addition of trimethylsilyl trifluoromethanesulfonate solution (1.0 mL of a 0.3M 
solution in CH3NO2, 0.34 mmol, 0.3 eq). The reaction mixture was allowed to warm to room 
temperature while stirring and progress was monitored by TLC using an eluent of 15% acetone 
in n-hexanes [98 Rf = 0.09, (-)-20 Rf = 0.19]. When full conversion to (-)-20 was observed by 
TLC, the reaction was quenched by the addition of a 1:1 mixture of saturated aqueous NaHCO3 
and brine, and diluted with Et2O. The organic layer was separated and the aqueous phase was 
extracted with Et2O. The combined organic phase was washed with brine and water before 
drying over MgSO4. After filtration, solvent evaporation, and purification by flash 
chromatography on silica gel (15% acetone in n-hexanes) the white foam (-)-20 was isolated 
(327 mg, 87%). Physical and spectral data with the exception of specific rotation were identical 
to those reported earlier in ACS Med. Chem. Lett. 2014, 5, 400−404. (-)-20 Rf = 0.16 (15% 
acetone in n-hexanes); [α]20D -62.5º (c 1.0, CHCl3) [lit.75 [α]20D -55.7° (c 1.0, CHCl3)]; 1H NMR 
(500 MHz, CDCl3) δ 6.81 (br s, 1H), 6.37 (d, J = 2.0 Hz, 1H), 6.33 (d, J = 2.0 Hz, 1H), 4.09 (ddd, 
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J = 15.0, 3.5, 2.5 Hz, 1H), 2.89 (ddd, J = 15.0, 11.5, 3.5 Hz, 1H), 2.63 (dddd, J = 15.0, 4.0, 3.5, 
2.0 Hz, 1H), 2.47 (ddd, J = 15.0, 13.5, 7.0 Hz, 1H), 2.21-2.11 (m, 2H), 1.97 (ddd, J = 12.0, 11.5, 
2.5 Hz, 1H), 1.56-1.46 (m, 3H), 1.48 (s, 3H) 1.28-1.15 (m, 6H), 1.21 (s, 6H) 1.13 (s, 3H), 
1.10-1.02 (m, 2H), 0.84 (t, J = 7.0 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 213.7, 154.7, 154.2, 
150.8, 107.7, 107.2, 105.5, 76.6, 47.3, 45.0, 44.3, 40.8, 37.3, 31.7, 29.9, 28.7, 28.6, 27.8, 26.8, 
24.5, 22.6, 18.8, 14.0; IR (neat) 3300, 2920, 1680, 1580, 1420, 1370, 1330, 1265 cm-1; HRMS 
ESI m/z: 373.2743 [M+H]+. Exact mass calculated for C24H36O3, 372.2655; found, 372.2648.
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In general: Protection was performed according to the general procedure outlined by Bunpei 
Hatano et al. in Green Chemistry, 2001, 3, 140–142.
Synthesis of 131 — (d; Scheme 17; Chpt. 3). A dry pear shaped flask equipped with a stir bar 
was charged with (-)-20 (219.0 mg, 0.587 mmol), imidazole (140.6 mg, 2.06 mmol, 3.5 eq), and 
t-butyldimethylsilyl chloride (177.3 mg, 1.18 mmol, 2 eq), and the flask was capped. The neat 
mixture of solids was heated to 80 ºC at which point the mixture became a pale yellow oil. 
Heating was continued for 1 hour and then the reaction mixture was cooled, diluted with 
hexanes and filtered through Celite®. The Celite® was washed with ether. The combined filtrate 
and wash were concentrated under reduced pressure and the resulting residue was suspended 
in hexanes and added to the top of a silica column. The column was eluted with hexanes 
followed by 8% EtOAc in hexanes to afford 131 (280.3 mg, 98% yield) as a colorless oil. (Rf = 
0.46 in 1:8 EtOAc:hexanes). [α]20D -12.0º (c 0.2, CHCl3); 1H NMR (500 MHz, CDCl3); δ 6.42 (d, J 
= 1.9 Hz, 1H), 6.34 (d, J = 1.9 Hz, 1H), 3.78 (ddd, J = 2.1, 3.4, 14.8 Hz, 1H), 2.72 (ddd, J = 3.4, 
11.1, 11.1 Hz, 1H), 2.56 (d, J = 15.0 Hz, 1H), 2.41 (m, 1H), 2.14 (m, 1H), 2.09 (dd, J = 13.5, 14.0 
Hz, 1H), 1.95 (ddd, J = 2.9, 12.4, 13.8 Hz, 1H), 1.52-1.46 (m, 3H), 1.47 (s, 3H), 1.23-1.15 (m, 
6H), 1.21, (s, 3H), 1.19 (s, 3H), 1.04 (m, 2H), 1.10 (s, 3H), 1.00 (s, 9H), 0.84 (t, J = 6.8 Hz, 3H), 
0.24 (s, 3H), 0.16 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 210.3, 154.2, 154.0, 150.1, 111.8, 
109.8, 108.4, 76.5, 47.8, 45.6, 44.5, 40.8, 37.4, 35.1, 31.8, 30.0, 28.9, 28.6, 27.8, 26.9, 26.0, 
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24.7, 22.6, 18.6, 18.3, 14.1, -3.7, -4.1; IR (neat) 3019, 2959, 2931, 2859, 1707, 1612, 1560, 
1472, 1413, 1332, 1256, 1185, 1111, 1097, 1057, 978, 841 cm-1; HRMS (ESI) m/z: 487.3601 [M
+H]+. Exact mass calculated for C30H50O3Si 486.3529; found 486.3529.
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In general: Homologation was performed according to the procedure outlined by Busch-
Peterson et al. in J. Med. Chem. 1996, 39, 3790-3796.
Synthesis of 132 — (A, B, C; Scheme 17; Chpt. 3). A dry 2-neck round bottom flask equipped 
with a 3-way gas inlet, stir bar, and septum under nitrogen was charged with (methoxymethyl)-
triphenylphosphonium chloride (1.02 g, 2.97 mmol, 8.4 eq) followed by anhydrous THF (10 mL). 
The reaction vessel was cooled to −30 °C before the slow addition of n-BuLi (1.20 mL of a 
2.09M in hexanes, 2.51 mmol, 7.1 eq). The resulting orange suspension, was allowed to warm 
to 0 ºC over 30 minutes, at which point the color changed to blood red. In a separate dry flask 
131 (172.2 mg, 0.353 mmol) was suspended in anhydrous THF (5 mL) under N2, cooled to -30 
ºC and then added to the 2-neck flask via cannula, keeping the temperature at 0 ºC or below. 
Stirring was continued at 0 ºC until the reaction was complete, as determined by TLC (30 min). 
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To the resulting red reaction mixture was added water and the mixture was stirred at room 
temperature until it became colorless (~30 min). The mixture was poured into water and 
extracted with ether (2x). The combined organic extract was washed with brine, dried over 
MgSO4 and concentrated under reduced pressure to provide crude enol ether. [Using a 1:4 
EtOAc:n-hexanes eluent. enol ether Rf = 0.85; 131 Rf = 0.57] 
The resulting crude enol ether residue (~800 mg) was dissolved in CH2Cl2 (20 mL) and 
wet trichloroacetic acid (404.4 mg, 2.47 mmol, 7 eq) was added in one portion. The mixture was 
stirred at room temperature until hydrolysis of the enol ether was complete, as determined by 
TLC (~1 h). The reaction was quenched with aqueous NaHCO3, and the mixture was extracted 
with CH2Cl2 (2x). The combined organic layers were washed with water and brine, dried over 
MgSO4, and concentrated to afford the aldehyde as a 2:1 mixture of epimers. [Using a 1:4 
EtOAc:n-hexanes eluent the inseparable mixture of epimers has a Rf = 0.68]
To a dry flask was added freshly powdered, anhydrous K2CO3 (380.4 mg, 2.75 mmol, 6 
eq) and the flask was purged with N2. In a separate flask, the epimeric mixture of aldehydes 
was dissolved in absolute ethanol (10 mL) under nitrogen and then transferred to the flask 
containing K2CO3 powder via cannula. The reaction mixture was stirred for 4 h at ambient 
temperature. The reaction was monitored by 1H NMR, using the disappearance of the α-
aldehyde to confirm full conversion to the β-aldehyde. [1H NMR (300 MHz, CDCl3):  α-aldehyde 
proton at 9.88, β- at 9.62]. The reaction was then quenched with aqueous NaH2PO4 and diluted 
with DCM. The aqueous phase was separated and extracted with DCM. The combined organic 
layers were washed with water then brine, dried over MgSO4, concentrated under reduced 
pressure and the resulting residue was purified by flash chromatography (0% to 10% EtOAc:n-
hexanes gradient) to give 132 (150.7 mg, 85% overall yield). Rf = 0.55 (1:8 EtOAc:n-hexanes 
eluent); [α]20D -59.6º (c 0.2, CHCl3); 1H NMR (500 MHz, CDCl3); δ 9.63 (s, 1H), 6.39 (d, J = 1.9 
Hz, 1H), 6.32 (d, J = 1.9 Hz, 1H), 3.49 (d, J =  12.9 Hz, 1H), 2.48-2.27 (m, 1H), 2.41 (ddd, J = 
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2.9, 11.4, 11.4 Hz, 1H), 2.15-1.92 (m, 1H), 2.10 (d, J = 13.5 Hz, 1H), 1.99 (d, J = 11.3 Hz, 1H), 
1.53-1.43 (m, 4H), 1.39 (s, 3H), 1.33-1.11 (m, 4H), 1.20 (s, 3H), 1.19 (s, 3H), 1.11-0.94 (m, 2H), 
1.07 (s, 3H), 1.01 (s, 9H), 0.91-0.79 (m, 2H), 0.84 (t, J = 6.9 Hz, 3H), 0.25 (s, 3H), 0.14 (s, 3H); 
13C NMR (75 MHz, CDCl3) δ  203.3, 154.4, 154.2, 149.2, 113.4, 109.7, 108.4, 76.6, 49.6, 44.5, 
40.5, 37.2, 35.4, 33.2, 31.8, 30.0, 29.8, 28.9, 28.6, 27.6, 27.5, 25.9, 24.6, 22.6, 18.8, 18.2, 14.0, 
-3.6, -4.3 ; IR (neat) 3020, 2959, 2931, 2859, 1722, 1612, 1564, 1468, 1412, 1263, 1216, 1141, 
1063, 908, 841, 756, 668 cm-1; HRMS (ESI) m/z: 501.3768 [M+H]+. Exact mass calculated for 
C31H52O3Si 500.3686; found 500.3690.
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Synthesis of 133 — (b; Scheme 18; Chpt. 3). A dry round bottom flask equipped with a stir bar 
and septum was charged 132 (62.5 mg, 0.124 mmol) under N2. The flask was cooled to 0 ºC 
and EtOH (3.5 mL) was added, followed by the portion-wise addition of NaBH4 (19.8 mg total, 
0.52 mmol, 4.2 eq). Stirring was continued at 0 ºC until complete conversion to alcohol was 
confirmed by TLC (~30 min). The reaction was quenched by the addition of 10% aqueous acetic 
acid, and diluted with EtOAc. The aqueous layer was separated and extracted with EtOAc. The 
combined organic layers were washed with brine, dried over MgSO4, and concentrated in 
vacuo. The crude material was purified by flash chromatography (5% and then 10% EtOAc in 
hexanes eluent) to provide 133 (51.3 mg, 82% yield) as a pale yellow oil. Rf = 0.19 (1:8 
EtOAc:n-hexanes eluent);  [α]20D -63.4º (c 0.2, CHCl3); 1H NMR (500MHz, CDCl3) δ 6.38 (d, J = 
1.9 Hz, 1H), 6.31 (d, J = 1.9 Hz, 1H), 3.54 (dd, J = 5.6, 10.6 Hz, 1H), 3.44 (dd, J = 6.9, 10.6 Hz, 
1H), 3.16 (d, J = 12.8 Hz, 1H), 2.36 (ddd, J = 2.6, 11.0, 11.0 Hz, 1H), 2.00 (m, 1H), 1.91 (m, 1H), 
1.71 (m, 1H), 1.51-1.44 (m, 3H), 1.38 (s, 3H), 1.27- 1.10 (m, 9H), 1.20 (s, 3H), 1.18 (s, 3H), 1.06 
(s, 3H), 1.03 (m, 2H), 1.00 (s, 9H), 0.83 (t, J = 7.0 Hz, 3H), 0.76 (dddd, J = 11.8, 11.9, 11.9, 
12.0, 1H), 0.23 (s, 3H), 0.16 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 154.4, 154.2, 149.2, 113.4, 
109.7, 108.4, 76.6, 68.5, 49.6, 40.5, 37.2, 35.5, 33.2, 31.8, 30.0, 29.8, 28.9, 28.6, 27.6, 27.5, 
26.2, 25.9, 24.7, 22.6, 18.8, 18.2, 14.1, -3.6, -4.4; IR (neat) 3320, 3020, 2959, 2931, 1612, 
1564, 1468, 1412, 1263, 1216, 1141, 1063, 908, 841, 756, 668 cm-1; HRMS (ESI) m/z: 
503.3905 [M+H]+. Exact mass calculated for C31H54O3Si 502.3842; found 502.3842.
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Synthesis of 135 — (a; Scheme 19; Chpt. 3). a. A dry 2-neck round bottom flask equipped 
with a reflux condenser, stir bar and septum was charged 133 (15.1 mg, 0.03 mmol) followed by 
imidazole (12.2 mg, 0.18 mmol, 6 eq), and iodine (15.2 mg, 0.06 mmol, 2 eq) at room 
temperature under argon. Benzene (0.5 mL) was added and a solution of triphenylphosphine 
(0.06 mL of a 1.0 M solution in benzene, 0.06 mmol, 2 eq) was added to the reaction vessel. 
The reaction mixture was heated at 90 ºC for 1 h and then cooled to room temperature. The 
reaction mixture was diluted with Et2O. The ethereal layer was the washed sequentially with 
water, aqueous sodium thiosulfate, and brine, then dried over MgSO4. After filtration and 
evaporation of solvent, the iodide 135 was used for the next step without further purification. 
[Using a 1:8 EtOAc:n-hexanes eluent; 133 Rf = 0.19, 135 Rf = 0.63].
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Synthesis of 84 — (d, f; Scheme 19; Chpt. 3). Crude iodide 135 (ca. 18 mg) was suspended 
at room temperature in anhydrous CH3CN (1 mL) under N2 in a dry, 2-neck round bottom flask 
equipped with a 3-way gas inlet, stir bar, and septum. The septum was opened under a small 
stream of nitrogen and AgNO3 (24.9 mg, 0.146 mmol, 5 eq) was introduced. Immediately a 
yellow precipitate formed, and the reaction was allowed to stirred at room temperature until full 
consumption of 135 was determined by TLC (~12 h). The reaction mixture was filtered through 
Celite® and the Celite® was washed with Et2O. The ethereal mixture was washed with brine, 
dried over MgSO4, and concentrated under reduced pressure.
The resulting residue was suspended in anhydrous Et2O (3 mL) and to this suspension 
was added tetrabutylammonium fluoride (0.04 mL of a 1M solution in THF, 0.41 mmol, 1.4 eq). 
The reaction mixture was stirred at room temperature for 1 hour before addition of water and 
extraction with Et2O (2x). The combined ethereal layers were washed with brine, dried over 
MgSO4, and  concentrated under reduced pressure. Purification by flash chromatography (15% 
EtOAc in hexanes eluent) provided 84 (10.5 mg, 82% overall yield, from 15.1 mg 133). [α]20D 
-29.8° (c 0.2, CHCl3); 1H NMR (500 MHz, CDCl3) δ 6.36 (d, J = 1.8 Hz, 1H), 6.18 (d, J = 1.8 Hz, 
1H), 4.63 (s, 1H), 4.37 (dd, J = 5.7, 10.5 Hz, 1H), 4.29 (dd, J = 6.8, 10.5 Hz, 1H), 3.24 (d, J = 
12.9 Hz, 1H), 2.49 (ddd, J = 2.8, 11.1, 11.1 Hz, 1H), 2.08-1.97 (m, 1H),  2.00 (d, J = 12.9 Hz, 
1H), 1.93 (d, J = 12.0 Hz, 1H), 1.53-1.46 (m, 3H), 1.39 (s, 3H), 1.27-1.12 (m, 8H), 1.20 (s, 6H), 
1.09 (s, 3H), 1.05 (m, 2H), 0.91 (m, 1H), 0.84 (t, J = 6.9 Hz, 3H) 13C NMR (125 MHz, CDCl3) δ 
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154.6, 154.2, 150.3, 108.9, 108.0, 105.4, 77.9, 48.9, 44.4, 37.3, 35.9, 34.8, 32.9, 31.8, 30.0, 
29.8, 28.7, 28.6, 27.7, 27.1, 24.6, 22.7, 19.0, 14.1, 1.0; IR (neat) 3463, 3054, 2986, 1652, 1648, 
1635, 1421, 1265, 895, 744, 705 cm-1; HRMS (ESI) m/z: 434.2898 [M+H]+. Exact mass 
calculated for C25H39NO5 433.2828; found 433.2824.
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Synthesis of 88 — (b, f; Scheme 19; Chpt. 3). A dry round bottom flask equipped with a stir 
bar and septum was charged with NaN3 (10.1 mg, 0.155 mmol, 5 eq) under N2. In a separate 
flask, crude iodide 135 was dissolved in anhydrous DMF (5 mL) under N2, and transferred via 
cannula to the flask containing NaN3. The resulting reaction mixture was stirred at ambient 
temperature until the consumption of 135 was complete as determined by TLC (~12 h). EtOAc 
and water were added to the reaction mixture, and the material was transferred to a separatory 
funnel where the layers were separated and the aqueous layer was further extracted with 
EtOAc. The combined organic layers were washed with water, dried over MgSO4, and 
concentrated under reduced pressure. [Using 1:10 EtOAc:n-hexanes eluent: 135 Rf = 0.78]
The resulting residue was suspended in anhydrous Et2O (3 mL) and to this suspension 
was added tetrabutylammonium fluoride (0.04 mL of a 1M in THF, 0.41 mmol, 1.4 eq). The 
reaction mixture was stirred at room temperature for 1 hour before addition of water and 
extraction with Et2O (2x). The combined ethereal layers were washed with brine, dried over 
MgSO4, and  concentrated under reduced pressure. Purification by flash chromatography (15% 
EtOAc in hexanes eluent) provided 84 (9.5 mg, 76% overall yield, from 15.3 mg of hydroxy 133). 
Rf = 0.22 (1:10 EtOAc:n-hexanes eluent); [α]20D -67.3° (c 0.2, CHCl3); 1H NMR (500 MHz, CDCl3) 
δ 6.36 (d, J = 1.8 Hz, 1H), 6.18 (d, J = 1.8 Hz, 1H), 4.65 (s, 1H), 3.26 (dd, J = 6.1, 12.0 Hz, 1H), 
3.20 (br d, J = 12.7 Hz, 1H), 3.15 (dd, J = 7.0, 12.0 Hz, 1H), 2.47 (ddd, J = 2.8, 11.1, 11.1 Hz, 
1H), 1.98 (m, 1H), 1.92 (m, 1H), 1.83 (m, 1H), 1.52-1.44 (m, 3H), 1.39 (s, 3H), 1.28-1.11 (m, 
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8H), 1.20 (s, 6H), 1.09 (s, 3H), 1.05 (m, 2H), 0.90-0.81 (m, 1H), 0.84 (t, J = 7.0 Hz, 3H); 13C 
NMR (125 MHz, CDCl3) δ 154.6, 154.2, 150.1, 109.2, 108.0, 105.4, 76.8, 57.8, 49.0, 44.4, 38.1, 
37.3, 34.9, 34.1, 31.8, 30.8, 30.0, 28.7, 28.6, 27.7, 27.4, 24.6, 22.7, 19.0, 14.1; IR (neat); 3386, 
3019, 2930, 2871, 2400, 2100, 1623, 1572, 1414, 1331, 1215, 1138, 1038, 670 cm-1; HRMS 
(ESI) m/z: 412.2972 [M-H]+. Exact mass calculated for C25H39N3O2 413.3042; found 413.3046.
 130
Synthesis of 86 — (c, f; Scheme 19; Chpt. 3). A dry round bottom flask equipped with a stir 
bar and septum was charged with NaCN (8.8 mg, 0.18 mmol, 6 eq) under N2. In a separate 
flask, crude iodide 135 was dissolved in anhydrous DMSO (2 mL) under N2 and transferred via 
cannula to the flask containing sodium cyanide. The resulting reaction mixture was stirred at 
ambient temperature until the consumption of 135 was complete as monitored by TLC (~12 h). 
EtOAc and water were added to the reaction mixture, and the material was transferred to a 
separatory funnel where the layers were separated and the aqueous layer was further extracted 
with EtOAc. The combined organic layers were washed with water then brine, dried over 
MgSO4, and concentrated under reduced pressure. [Using 1:10 EtOAc:n-hexanes eluent: 135 Rf 
= 0.78]
The resulting residue was suspended in anhydrous Et2O (3 mL) and to this suspension 
was added tetrabutylammonium fluoride (0.04 mL of a 1M in THF, 0.41 mmol, 1.4 eq). The 
reaction mixture was stirred at room temperature for one hour before addition of water and 
extraction with Et2O (2x). The combined ethereal layers were washed with brine, dried over 
MgSO4, and  concentrated under reduced pressure. Purification by flash chromatography (0%, 
10%, 20% and then 33% EtOAc in hexanes stepwise gradient) provided 88 (9.2 mg, 77% 
overall yield, from 15.1 of hydroxy 133). Rf = 0.22 (1:10 EtOAc:n-hexanes eluent); [α]20D -65.0° 
(c 0.2, CHCl3);  1H NMR (500 MHz, CDCl3) δ 6.36 (d, J = 1.7 Hz, 1H), 6.18 (d, J = 1.7 Hz, 1H), 
4.68 (s, 1H), 3.30 (dddd, J = 2.7, 2.8, 2.9, 12.8 Hz, 1H), 2.49 (ddd, J = 2.8, 11.1, 11.1 Hz, 1H), 
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2.36 (dd, J = 6.1, 16.7 Hz, 1H), 2.29 (dd, J = 6.9, 16.7 Hz 1H), 2.06 (d, J = 12.0 Hz, 1H), 
2.00-1.89 (m, 2H), 1.53-1.45 (m, 3H), 1.39 (s, 3H), 1.32-1.11 (m, 8H), 1.19 (s, 6H), 1.09 (s, 3H), 
1.05 (m, 2H), 0.97 (ddd, J = 11.9, 12.0, 12.0 Hz, 1H), 0.84 (t, J = 7.1 Hz, 3H); 13C NMR (125 
MHz, CDCl3) δ 154.6, 154.2, 150.3, 118.7, 108.8, 108.0 105.3, 77.2, 48.6, 44.4, 37.3, 36.0, 
35.0, 34.7, 32.5, 31.8, 30.0, 28.7, 28.6, 27.7, 27.3, 24.6 (2C), 22.7, 19.0, 14.1; IR (neat); 3396, 
3054, 2986, 2253, 1623, 1575, 1415, 1265, 909 cm-1; HRMS (ESI) m/z: 396.2909 [M-H]+. Exact 
mass calculated for C26H39NO2 397.2981; found 397.2982.
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In general. This reaction was performed following the work of Augustine, J. K. et al. in Synlett, 
2011, 2223-2227.
Synthesis of 85 — (c; Scheme 21; Chpt. 3). To a vial equipped with a stir bar was added 130 
(14.1 mg, 0.036 mmol) followed by hydroxylamine hydrochloride (3.1 mg, 0.043 mmol, 1.2 eq) 
and DMSO (0.3 mL). The vial was capped and heated at 90 ºC for 1 h. The reaction mixture 
was cooled to room temperature and water and Et2O were added to the vial. The aqueous layer 
was removed and extracted with Et2O. The combined ethereal layers were washed with water 
then brine, dried over MgSO4, and  concentrated under reduced pressure. The resulting residue 
was purified by flash chromatography (0% to 8% EtOAc in hexanes gradient) to provide 85 
(12.0 mg, 86% yield) as a white amorphous solid. Rf = 0.49 (1:4 EtOAc:n-hexanes); [α]20D -32.0° 
(c 0.2, CHCl3); 1H NMR (500 MHz, CDCl3) δ 6.36 (d, J = 1.8 Hz, 1H), 6.19 (d, J = 1.8 Hz, 1H), 
4.80 (s, 1H), 3.61 (d, J = 13.5 Hz, 1H), 2.68 (dddd, J = 3.8, 3.8, 12.5, 12.5 Hz, 1H), 2.43 (ddd, J 
= 2.8, 11.2, 11.2 Hz, 1H), 2.27 (d, J = 13.6 Hz, 1H), 1.95 (dddd, J = 2.8, 2.8, 2.9, 13.0 Hz, 1H), 
1.72 (dddd, J = 4.1, 12.9, 13.0, 13.0 Hz, 1H), 1.54 (ddd, J = 2.6, 11.8, 11.9 Hz, 1H), 1.51-1.46 
(m, 2H), 1.43-1.33 (m, 1H), 1.38 (s, 3H), 1.28-1.08 (m, 7H), 1.19 (s, 6H), 1.08-1.00 (m, 2H), 
1.07 (s, 3H), 0.84 (t, J = 7.0 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 154.5, 154.1, 150.7, 122.5, 
108.1, 107.6, 105.4, 76.4, 47.9, 44.4, 37.3, 34.7, 33.3, 31.8, 30.1, 30.0, 28.7, 28.6, 28.3, 27.5, 
26.9, 24.6, 22.6, 19.0, 14.1; IR (neat); 3396, 3054, 2986, 2253, 1623, 1575, 1415, 1265, 909 
cm-1; HRMS (ESI) m/z: 384.2895 [M+H]+. Exact mass calculated for C25H37NO2 383.2824; found 
383.2822.
 133
O
OH
O
130
H
O
OH
CN
85
In general. The reductive amination was carried out according to Ayedi, M. A., et al. in Synth. 
Commun., 2013, 43, 2127–2133. Formation of isothiocyanate followed the work of Ogawa, G. et 
al. in J. Med. Chem., 2015, 58, 3104−3116.
Synthesis of 90 — (a, b; Scheme 22; Chpt. 3). A dry 2-neck round bottom flask equipped with 
a 3-way gas inlet, stir bar, and septum was charged with 130 (15.0 mg, 0.038 mmol) at room 
temperature, under N2. Absolute EtOH (0.5 mL) followed by hydroxylamine hydrochloride (6.7 
mg, 0.097 mmol, 2.5 eq) was added to the flask under a stream of nitrogen. The reaction 
mixture was allowed to stir at room temperature until the starting materials were consumed 
completely as determined by TLC (~16 h). To the flask was added zinc dust (12.4 mg, 0.189 
mmol, 4.9 eq) followed by conc. hydrochloric acid (three drops, ca. 41.3 mg, 0.419 mmol, 11.8 
eq). Stirring was continued for 30 minutes and reaction mixture became a slurry. A solution of 
aqueous ammonia (30%, 7 mL) and sodium hydroxide (6M, 15 mL) was added dropwise to the 
slurry, and the mixture was stirred at room temperature for 15 minutes. The reaction mixture 
was transferred to a separatory funnel and extracted with dichloromethane twice. The combined 
organic layers were dried over Na2SO4, and concentrated under reduced pressure to afford 137, 
which was used without further purification.
Crude 137 (ca. 14 mg) was dissolved in anhydrous THF (2 mL) under a nitrogen 
atmosphere, and cooled to 0 ºC. Triethylamine (0.05 mL, 0.389 mmol, 10 eq) was added to the 
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reaction flask slowly, followed by the dropwise addition of carbon disulfide (0.09 mL, 1.48 mmol, 
41 eq). Stirring was continued at 0 ºC for 30 minutes at which point more carbon disulfide (0.09 
mL, 1.48 mmol, 41 eq) was added dropwise. The temperature was maintained at 0º C and 
stirring continued for 90 minutes. Solid p-toluenesulfonyl chloride (6.89 mg, 0.036 mmol, 1.0 eq) 
was then added in one portion. The reaction mixture was allowed to warm to room temperature 
and was stirred for an additional 90 minutes before quenching with pH 7 phosphate buffer. The 
mixture was diluted with Et2O and transferred to a separatory funnel where the aqueous phase 
was separated and extracted with Et2O. The ethereal layers were combined, washed with brine, 
dried over Na2SO4, and concentrated under reduced pressure. Purification by flash 
chromatography (0% — 5% EtOAc in hexanes eluent) provided 90 (10.1 mg, 61% overall yield) 
as a white amorphous solid. Rf = 0.73 (1:4 EtOAc:n-hexanes); [α]20D -65.0° (c 0.2, CHCl3); 1H 
NMR (500 MHz, CDCl3) δ 6.36 (d, J = 1.8 Hz, 1H), 6.18 (d, J = 1.8 Hz, 1H), 4.66 (br s, 1H), 3.47 
(dd, J = 5.6, 14.1 Hz, 1H), 3.40 (dd, J = 6.4, 14.2 Hz, 1H), 3.24 (d, J = 12.1 Hz, 1H), 2.49 (ddd, J 
= 2.7, 11.1, 11.1 Hz, 1H), 2.03-1.89 (m, 3H), 1.53-1.45 (m, 3H), 1.39 (s, 3H), 1.28-1.11 (m, 8H), 
1.19 (s, 6H), 1.09 (s, 3H), 1.05 (m, 2H), 0.92 (m, 1H), 0.84 (t, J = 6.9 Hz, 3H); 13C NMR (125 
MHz, CDCl3) δ 154.6, 154.2, 150.2, 129.7, 108.9, 108.0, 105.4, 77.0, 51.0, 48.8, 44.4, 38.5, 
37.3, 34.8, 33.8, 31.8, 30.5, 30.0, 28.7, 28.6, 27.7, 27.2, 24.6, 22.7, 19.0, 14.1; IR (neat) 3408, 
3960, 2930, 2860, 2192, 2108, 1623, 1574, 1466, 1413, 1389, 1333, 1265, 1139, 1038 cm-1; 
HRMS (ESI) m/z: 428.2619 [M-H]+. Exact mass calculated for C26H39NO2S 429.2692, found 
429.2702.
 135
Synthesis of 141 — (a; Scheme 24; Chpt. 3). A dry round bottom flask equipped with a stir bar 
and septum was charged with 131 (137.1 mg, 0.281 mmol) under N2. The flask was cooled to 0 
ºC and EtOH (5 mL) was added to it, followed by the portion-wise addition of NaBH4 (42.6 mg 
total, 1.13 mmol, 4.0 eq). Stirring was continued at 0 ºC until the reaction was complete, as 
judged by TLC (~1 h). The reaction was quenched by the addition of 10% aqueous acetic acid, 
and diluted with EtOAc. The aqueous layer was separated and extracted with EtOAc. The 
combined organic layers were washed with brine, dried over MgSO4, and concentrated under 
reduced pressure. The crude residue was purified by flash chromatography (5% - 10% EtOAc in 
hexanes gradient) to provide 141 (114.3 mg, 83% yield) as a white amorphous solid. Rf = 0.48 
(1:4 EtOAc:n-hexanes); [α]20D -75.4º (c 0.2, CHCl3); 1H NMR (500 MHz, CDCl3) δ 6.39 (d, J = 
1.9 Hz, 1H), 6.32 (d, J = 1.9 Hz, 1H), 3.77 (dddd, J = 4.5, 4.9, 10.5, 11.0 Hz, 1H), 3.38 (d, J = 
12.0 Hz, 1H), 2.34 (ddd, J = 2.5, 11.2, 11.2 Hz, 1H), 2.17 (d, J = 12.4 Hz, 1H), 1.88 (dddd, J = 
3.2, 3.4, 3.5, 12.8 Hz, 1H), 1.53-1.45 (m, 3H), 1.41-1.34 (m, 2H), 1.38 (s, 3H), 1.26-1.12 (m, 
7H), 1.20 (s, 3H), 1.19 (s, 3H), 1.10-1.00 (m, 3H), 1.05 (s, 3H), 1.02 (s, 9H), 0.84 (t, J = 7.0 Hz, 
3H), 0.24 (s, 3H), 0.14 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 154.3, 154.3, 149.4, 112.7, 109.7, 
108.4, 76.6, 70.8, 48.7, 44.5, 39.5, 37.3, 35.8, 33.9, 31.8, 30.0, 28.9, 28.6, 27.8, 26.2, 25.9, 
24.7, 22.6, 18.8, 18.2, 14.1, -3.7, -4.3; IR (neat) 3320, 2920, 1634, 1565, 1470, 1410, 775, 665 
cm-1 ; HRMS (ESI) m/z: 489.3759 [M+H]+. Exact mass calculated for C30H52O3Si 488.3686, 
found 488.3687.
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Synthesis of 140 — (b; Scheme 24; Chpt. 3). b. A dry 2-neck round bottom flask equipped 
with a 3-way gas inlet, stir bar, and septum was charged with imidazole (14.2 mg, 0.208 mmol, 6 
eq), and iodine (17.6 mg, 0.07 mmol, 2 eq) followed by addition of a solution of 139 (0.58 mL as 
0.06M solution in benzene, 17.1 mg, 0.034 mmol) at room temperature under argon. To the 
mixture was then added a solution of triphenylphosphine (0.06 mL of a 1M solution in benzene, 
0.06 mmol) and reaction mixture was heated for 1 hour at 45 ºC and then cooled to room 
temperature. The complete consumption of 139 was confirmed by TLC and the reaction mixture 
was diluted with Et2O. The ethereal layer was separated, washed with water then aqueous 
sodium thiosulfate, brine, and dried over MgSO4. Concentration in vacuo provided iodide 140 
which was used for the next step without further purification. [1:10 EtOAc:n-hexanes eluent: 139 
Rf = 0.15, 140 Rf = 0.77].
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Synthesis of 87 — (c, e; Scheme 24; Chpt. 3) A dry round bottom flask equipped with a stir 
bar and septum was charged with sodium azide (13.5 mg, 0.208 mmol, 6 eq) under N2. In a 
separate flask, crude iodide 140 was dissolved in anhydrous DMF (5 mL) under N2, and 
transferred via cannula to the flask containing sodium azide. This reaction mixture was stirred at 
ambient temperature for 12 hours. When the 140 was completely consumed as determined by 
TLC, EtOAc and water were added to the reaction mixture. The reaction mixture was transferred 
to a separatory funnel where aqueous layer was removed and was further extracted with EtOAc. 
The combined organic layers were washed with water, brine, dried over MgSO4, and 
concentrated under reduced pressure. [1:12 EtOAc:n-hexanes eluent: 140 Rf = 0.75]
The resulting residue was suspended in anhydrous Et2O (3 mL) and to this suspension 
was added tetrabutylammonium fluoride (0.04 mL of a 1M in THF, 0.41 mmol, 1.4 eq). The 
reaction mixture was stirred at room temperature for one hour before addition of water and 
extraction with Et2O (2x). The combined ethereal layers were washed with brine, dried over 
MgSO4, and concentrated under reduced pressure. Purification by flash chromatography (0% - 
1% acetone in hexanes gradient) provided 87 (9.4 mg, 76% overall yield). Rf = 0.13 (1:10 
EtOAc:n-hexanes eluent); [α]20D -54.5º (c 0.2, CHCl3); 1H NMR (500 MHz, CDCl3) δ 6.37 (d, J = 
1.8 Hz, 1H), 6.19 (d, J = 1.8 Hz, 1H), 4.74 (s, 1H), 3.53-3.46 (m, 2H), 2.50 (ddd, J = 2.2, 11.2, 
11.2 Hz, 1H), 2.17 (d, J = 12.3 Hz, 1H), 1.95 (dddd, J = 2.8, 3.1, 3.1, 13 Hz, 1H), 1.55-1.42 (m, 
4H), 1.39 (s, 3H), 1.27-1.11 (m, 8H), 1.20 (s, 6H), 1.08 (s, 3H), 1.05 (m, 2H), 0.84 (t, J = 6.9 Hz, 
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3H); 13C NMR (125 MHz, CDCl3) δ 154.6, 154.1, 150.4, 108.3, 108.0, 105.4, 76.7 (under 
CDCl3), 59.9, 48.1, 44.4, 37.3, 35.1, 33.9, 32.0, 31.8, 30.0, 28.7, 28.6, 27.8, 26.4, 24.6, 22.7, 
19.0, 14.1; IR (neat) 3431, 3019, 2931, 2872, 2098, 1643, 1518, 1415, 758, 670 cm-1; HRMS 
(ESI) m/z: 400.2994 [M+H]+. Exact mass calculated for C24H37N3O2 399.2886, found 399.2890.
 139
Synthesis of 83 — (d, e; Scheme 24; Chpt. 3). Crude iodide 140 (ca. 18 mg) was dissolved at 
room temperature in anhydrous CH3CN (1 mL) under N2 in a dry, 2-neck round bottom flask 
equipped with a 3-way gas inlet, stir bar, and septum. The septum was opened under a small 
stream of nitrogen and AgNO3 (24.9 mg, 0.146 mmol, 5 eq) was introduced. Immediately a 
yellow color was observed, and the reaction mixture was allowed to stir at room temperature 
until consumption of 140 was complete as determined by TLC (~12 h). The reaction mixture was 
filtered through Celite® and the Celite® was washed with Et2O. The ethereal filtrate and washes 
were combined and washed with brine, dried over MgSO4, and concentrated under reduced 
pressure. 
The resulting residue was suspended in anhydrous Et2O (3 mL) and to this suspension 
was added tetrabutylammonium fluoride (0.04 mL of a 1M in THF, 0.41 mmol, 1.4 eq). The 
reaction mixture was stirred at room temperature for one hour before addition of water and 
extraction with Et2O (2x). The combined ethereal layers were washed with brine, dried over 
MgSO4, and concentrated under reduced pressure. Purification by flash chromatography (15% 
EtOAc in hexanes eluent) provided 83 (10.5 mg, 82% overall yield). [α]20D -40.5º (c 0.2, CHCl3); 
1H NMR (500 MHz, CDCl3) δ 6.37 (d, J = 1.8 Hz, 1H), 6.19 (d, J = 1.8 Hz, 1H), 5.13 (dddd, J = 
4.4, 4.5, 11.4, 11.5 Hz, 1H), 4.69 (s, 1H), 3.60 (dddd, J = 2.4, 2.4, 4.4,12.0 Hz, 1H), 2.58 (ddd, J 
= 2.7, 11.4, 11.5 Hz, 1H), 2.31 (d, J = 12.3 Hz, 1H), 2.00 (dddd, J = 3.0, 3.1, 3.8, 10.1 Hz, 1H), 
1.61-1.45 (m, 4H), 1.41 (s, 3H), 1.31-1.15 (m, 8H), 1.20 (s, 6H), 1.09 (s, 3H), 1.05 (m, 2H), 0.84 
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(t, J = 7.0 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 154.6, 154.0, 150.6, 108.1, 107.7, 105.4, 82.4, 
76.6, 48.0, 44.4, 37.3, 33.4, 33.2, 31.7, 30.1, 30.0, 28.7, 28.6, 27.8, 25.7, 24.6, 22.6, 19.0, 14.1; 
IR (neat) 3388, 2958, 2930, 2872, 1625, 1574, 1414, 1278, 760, 693 cm-1; HRMS (ESI) m/z:
418.2603 [M-H]+. Exact mass calculated for C24H37NO5 419.2672, found 419.2676.
 141
In general. Reductive amination procedure is adapted from the work of H.-W. Cui et al. in Eur J. 
Med. Chem., 2015, 95, 240-248
Synthesis of 89 — (a, b; Scheme 25; Chpt. 3). A dry screw cap vial equipped with a stir bar 
was charged with (-)-20 (14.4 mg, 0.038 mmol), ammonium acetate (44.6 mg, 0.579 mmol, 15 
eq) and sodium cyanoborohydride (3.6 mg, 0.057 mmol, 1.5 eq).  The vial was purged with N2, 
sealed temporarily with a septum, and placed in an ice bath. MeOH (0.5 mL) was added to the 
vial followed by acetic acid (0.01 mL, 0.193 mmol, 5 eq) and the reaction mixture was stirred 
until homogeneous. At this point the septum was replaced by a screw cap under a stream of 
nitrogen and the vial was placed in a 4 ºC refrigerator for 24 hours. The reaction mixture was 
concentrated under reduced pressure and basified to pH 9 using aqueous NaHCO3. This 
aqueous mixture was extracted with DCM. The organic layer was washed with brine, dried over 
Na2SO4, and concentrated under reduced pressure to provide amine 143 which was used 
without purification.
Crude 143 (ca. 14 mg) was dissolved in anhydrous THF (2 mL) under a nitrogen 
atmosphere, and cooled to 0 ºC. Triethylamine (0.05 mL, 0.389 mmol, 10 eq) was added to the 
reaction flask slowly, followed by the dropwise addition of carbon disulfide (0.09 mL, 1.48 mmol, 
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41 eq). Stirring continued at 0 ºC for 30 minutes at which point more carbon disulfide (0.09 mL, 
1.48 mmol, 41 eq) was added dropwise. The temperature was maintained at 0º C and stirring 
continued for 90 minutes. Solid p-toluenesulfonyl chloride (7.0 mg, 0.036 mmol, 1.0 eq) was 
added in one portion. The reaction mixture was allowed to warm to room temperature and ws 
stirred for an additional 90 minutes before quenching with pH 7 phosphate buffer. The mixture 
was diluted with Et2O and transferred to a separatory funnel where the aqueous phase was 
separated and extracted with Et2O. The ethereal layers were combined, washed with brine, 
dried over Na2SO4, filtered, and concentrated under reduced pressure. Purification by flash 
chromatography (0% and then 4% EtOAc in hexanes gradient) provided a 4.3:1 mixture of 89 
and 89-ax (12.2 mg,  76% overall yield) as a white amorphous solid. This mixture was further 
purified by normal phase HPLC over 30 min (15% - 30% EtOAc in hexanes gradient) to provide 
pure 89 (9.2 mg). [α]20D -85.0º (c 0.2, CHCl3); 1H NMR (500 MHz, CDCl3) δ 6.37 (d, J = 1.8 Hz, 
1H), 6.19 (d, J = 1.8 Hz, 1H), 4.69 (s, 1H), 3.76 (dddd, J = 4.2, 4.2, 11.7, 11.7 Hz, 1H), 3.62 
(dddd, J = 2.3, 2.5, 3.5, 12.5 Hz, 1H), 2.44 (ddd, J = 2.8, 11.4, 11.4 Hz, 1H), 2.30 (d, J = 11.7 
Hz, 1H), 1.92 (dddd, J = 2.7, 3.0, 3.6, 12.8, 1H), 1.66 (dddd, J = 4.2, 12.6, 12.7, 12.8 Hz, 1H), 
1.54-1.45 (m, 2H), 1.41-1.34 (m, 1H), 1.38 (s, 3H), 1.27-1.10 (m, 8H), 1.19 (s, 6H), 1.09-1.00 
(m, 2H), 1.06 (s, 3H), 0.84 (t, J = 7.0 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 154.6, 154.0, 
150.6, 130.0, 108.1, 107.7, 105.4, 76.5, 55.8, 47.8, 44.4, 37.3, 37.2, 34.0, 33.8, 31.8, 30.0, 28.7, 
28.6, 27.7, 26.2, 24.6, 22.7, 19.0, 14.1; IR (neat) 3406, 2958, 2930, 2171, 2117, 1624, 1574, 
1414, 1375, 1265, 738 cm-1; HRMS (ESI) m/z: 414.2475 [M-H]+. Exact mass calculated for 
C25H37NO2S 415.2545, found 415.2548.
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beautiful island of O‘ahu:  The culture of Hawai‘i is, like many sovereign nations, a complex 
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